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ABSTRACT
Malaria is considered as one of the most prevalent and debilitating diseases affecting
humans. Plasmodium falciparum is the most virulent form of the parasite which
developed resistance to several antimalarial drugs. Chloroquine is one of the most
successful antimalarials developed that is safe, effective, and cheap. However, its use has
been limited due to the emergence of drug resistance. Click chemistry, particularly, the
copper(I)-catalyzed reaction between azides and alkynes has shown to have a cuttingedge advantage in medicinal chemistry by its reliability, selectivity and biocompatibility.
Triazole-based antimalarials were synthesized via copper(I)-catalyzed alkyne-azide
cycloaddition reaction by modifying the aliphatic chain terminal of chloroquine. The
compounds synthesized contain triazole ring directly connected to an aromatic ring or via
a piperazine linker. When tested for their in vitro antimalarial activity against D6, Dd2
and 7G8 strains of P. falciparum, 12 out of 28 compounds showed better activity against
chloroquine resistant strains. Particularly, PL403 and PL448 exhibited potent activity
than chloroquine against CQ-resistant strains Dd2 and 7G8, with IC50 values of 12.8 &
14.5 nM, and 15.2 & 11 nM respectively.
The efficiency of synthesizing several triazole-based antimalarials have proven click
chemistry to be fast and efficient reaction. Generally, para-substitutions and disubstitutions with electron-withdrawing groups were found to be beneficial for having
better antimalarial activity for these group of click compounds. Moreover, the
incorporation of piperazine linker has brought an enhanced antimalarial activity.
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CHAPTER 1: Malaria
1.1. Introduction and Epidemiology
Malaria is a tropical infectious disease considered as one of the most prevalent and
debilitating diseases affecting humans.1 There are 3.4 billion people at risk of malaria
transmission in 106 countries and territories. The WHO estimates 198 million cases of
malaria and an estimated 584,000 deaths, many of them are children living in subSaharan Africa where a child dies every minute.2 Malaria was eliminated from the United
States in the early 1950's. However, 1500 – 2000 malaria cases are reported every year in
the US from recent travelers.3

Figure 1.1. % population at risk in 20132
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1.2. Cause and Transmission
Malaria is caused by infection with protozoan parasites belonging to the genus
Plasmodium transmitted by female Anopheles mosquitoes.4 Although over 200 species of
Plasmodium genus are existing, only five affect humans: P. falciparum, P. vivax, P.
ovale, P. malarie and P. knowlesi.5

Figure 1.2. Life cycle of Plasmodia species11
Plasmodium falciparum is the most virulent form which causes potentially fatal cerebral
malaria. It’s characterized by high levels of parasitaemia and is responsible for about
2

80% of human malaria worldwide.1, 5 Relapse is common with P. vivax and ovale due to
the dormant stage (hypnozoites) persisting in the liver and invading the blood stream in
later years. While P. vivax and P. ovale selectively infect young cells, P. malariae
parasitizes older cells.6 P. knowlesi is considered as a parasite of monkeys that can cause
fatal infections in humans.7
Species
Plasmodium
falciparum
Plasmodium
vivax
Plasmodium
ovale

Clinical features
Tertian non-relapsing malignant
malaria
Tertian relapsing benign
malaria
Tertian relapsing benign
malaria

Endemic areas
Sub-Saharan Africa, Latin
America, South-East Asia
South-East Asia, Latin
America, Sub-Saharan Africa
South-East Asia, Pacific, East
Africa

Plasmodium Quartan non-relapsing benign
West Africa, Guyana, India
malariae
malaria
Plasmodium Quotidian, Severe malaria may South-East Asia
knowlesi
occur
Table 1.1. Clinical features and geographical distribution of Plasmodia species8
The malaria parasite life cycle involves two hosts: human and mosquito. During a blood
meal, a Plasmodium-infected female Anopheles mosquito inoculates sporozoites into the
human host. Sporozoites infect liver cells and mature into schizonts, which rupture and
release merozoites. At this stage they can also remain dormant as hypnozoites.9 After the
initial replication in the liver, the parasites undergo asexual multiplication in the
erythrocytes. Merozoites infect red blood cells. The ring stage trophozoites mature into
schizonts, which rupture releasing merozoites. Some parasites differentiate into sexual
erythrocytic stages (gametocytes). Blood stage parasites are responsible for the clinical
manifestations of the disease.10
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The gametocytes, male and female, are ingested by an Anopheles mosquito during a
blood meal. While in the mosquito's stomach, the microgametes penetrate the
macrogametes generating zygotes. The zygotes in turn become motile and elongated
ookinetes which invade mosquito gut where they develop into oocysts.11 The oocytes give
birth to sporozoites in the gut of a female mosquito. These migrate to the mosquito's
salivary glands, and are injected into humans. Inoculation of the sporozoites into a new
human host perpetuates the malaria life cycle.12
1.3. Symptoms and Diagnosis
Following an infective bite by female Anopheles mosquito, the infected person starts to
show symptoms after 1 to 4 weeks. The most common symptoms of malaria include
fever, chills, sweating, headaches, fatigue, nausea, and vomiting.13 In P. falciparum
malaria, untreated patients present more pernicious manifestations such as cerebral
malaria, hypoglycemia, acute renal failure, metabolic acidosis, severe anemia, and
pulmonary edema.14 Severe anemia is a major cause of morbidity and mortality among
children in the developing countries.
Microscopy is the basis for diagnosis of malaria providing information about the species
and the density of Plasmodium. Polymerase chain reaction (PCR) is also used when the
detection limits of parasites is below microscopy.15 Antigen-detecting RDT detects
Plasmodium antigen by an antibody–antigen reaction on a nitrocellulose strip.16 Antibody
could also be detected by ELISA after exposure to the parasites. Moreover, hemozoin, a

4

by-product of Plasmodium metabolism, has been used to detect both the disease and the
species via the absorbance of laser light at specific frequencies.17
1.4. Treatment and Prevention
The Malaria Eradication Research Agenda (malERA) addressed several issues in malaria
elimination campaigns. It focuses on integrated research agenda which is essential in
making pragmatic decision for shifting from control to elimination.18 The global malaria
control strategy aims to halt the exacerbating situation of malaria by minimizing waste of
resources and improving health services.19
Insect repellents could provide useful protection against malaria, especially in places
where vector mosquitos bite early in the evening.20 Indoor residual spraying (IRS),
mainly through the use of the insecticide DDT (dichloro-diphenyl-trichloroethane) has
been an important component of malaria control. Despite attempts to ban DDT
completely because of issues such as effect on preterm births and lactation duration, the
compound continues to be used in parts of Asia and Africa.20, 21
Vector control is also an essential component of prevention.21 Insecticide-treated nets
(ITNs) have consistently shown reductions in overall child mortality and in episodes of
clinical malaria.20 In areas of moderate or high transmission in Africa, deployment of
pyrethroid insecticide-treated mosquito nets reduced all-cause mortality by roughly 20%
in children younger than 5 years.21 ITNs are more beneficiary than IRS as they both
protect the individual user against biting and kill some of the mosquitoes that try to bite.

5

Deltamethrin and Permethrin are the most commonly used insecticides constituting
about 60 and 22% of the global usage respectively.22
The genome of Anopheles gambiae, one of the most efficient vectors of malaria, has now
been sequenced providing candidate genes in generating Genetically Modified
Mosquitoes (GMM).24 This 20-year old program uses site-specific gene recombination
technologies to insert the antipathogen effector genes in the integration sites of the
genome to develop A. gambie that are fully refractory to plasmodium.22
Drug chemoprophylaxis has also proved to be one of the most effective preventive
strategy especially for travellers to malaria endemic areas. It is essential to emphasize that
no chemoprophylactic regimen gives complete protection and must always be
accompanied by primary protection such as ITN and insect repellants. The prophylaxis
drug should be continued to be taken for at least 4 weeks after the last possible exposure
to take into account for the pre-erythrocytic phase of the plasmodial cycle.8
Common antimalarials used as chemoprophylactic agents include chloroquine, proguanil,
mefloquine, doxycycline, primaquine and tefenoquine. Proguanil in combination with
chloroquine and atovaquone (Malorone) is also administered. Some antimalarial drugs
that have well established therapeutic roles have no rational use as malaria
chemotherapeutic agents (Table 2). Although chloroquine is less useful as
chemoprophylaxis in most places, it is still used in Central America and Hispaniola. In
the US, mefloquine (1989), doxycycline (1992) and atovaquone/proguanil (2001) are the
three currently approved drugs for malaria prevention.8, 25
6

Antimalarial drug

Severe adverse event or contraindication
observed
Amodiaquine
agranulocytosis and hepatotoxicity
Halofantrine
cardiac dysrhythmias
Pyrimethamine-dapsone Agranulocytosis
Pyrimethaminesevere skin reactions (e.g. Stevens-Johnson
sulfadoxine
syndrome)
Quinine
long-term use predisposes to blackwater fever
qinghaosu derivatives
severe CNS lesions in animal studies in long-term
(i.e. artesunate)
use of these short-acting drugs
Table 1.2. Medications that should not be used for malaria chemoprophylaxis

The WHO recommends occupational and long-term travellers to carry Stand-By
Emergency Treatment (SBET) drugs for self treatment when medical care is not
accessible within 24 hours from onset of exposure and symptoms. Combination drugs
used for uncomplicated P. falciparum malaria such as artemether/lumefantrine,
atovaquone-proguanil, quinine plus doxycycline or clindamycin can be used as SBET
drugs.8
Almost two decades have been spent on development of malaria vaccines. So far, most
efforts have been put in developing pre-erythrocytic stage vaccines designed to destroy
infected hepatocytes or prevent their invasion by sporozoites.20 RTS,S/AS01 is a hybrid
molecule in which the circumsporozoite protein of P. falciparum is expressed with
hepatitis-B surface antigen (HBsAg) in yeast and boosted with the potent ASO
adjuvant.21
In coincidence with World Malaria Day 2015, the RTS,S Clinical Trials Partnership
reported final results of a Phase 3 trial of the RTS,S/AS01 vaccine which were conducted
in seven countries in Africa. After 38 and 48 months, the results indicated 25.9 and
7

36.3% protection in children at 6-12 weeks and 5-7 months respectively when 3 doses
were given at 0, 1, 2 with a booster at 20 months or a control vaccine.26
Moreover, various medicinal plants are reported to possess insect-repellent activity
against mosquitoes including Azadirachta indica, Lantana camara, Vitex negundo,
Mentha piperita, Tagetes minuta, Eucalyptus and Cymbopogon species.23 In some
definite epidemiological situations, environmental management activies comprising
drainage of mosquitoes breeding sites, house design improvements and utilising
larvivorous fish have proved to be effective.20
1.5. Antimalarial Chemotherapy
When malaria prevention fails and a person is infected by the parasite, several treatment
options are available. The treatment depends on the type the Plasmodium species, the
stage of the parasite, the mechanism of action and the half life of the drug.
Quinine was the first natural antimalarial extracted from the bark of cinchona tree in Peru
around the 17th century. It was the pioneer drug and has been used for more than two
centuries until its resistance emerged.27 In addition, the common side effect symptoms of
cinchonism associated with it decreased its use. Because of resistance, quinine is taken in
combination with secondary agents such as doxycycline, clindamycin or SP. Although its
sterioisomer, quinidine, could be given IV for P. falciparum malaria, it is basically
indicated as anti-arrhythmic.29
The 4-aminoquinolines are an important class of antimalarials which comprises of
chloroquine, amodiaquine and piperaquine.27 Chloroquine is one of the classic drugs
8

which became a mainstay for malaria treatment in the mid-20th century. Chloroquine and
amodiaquine have blood schizontocidal effects against asexual stages of the parasite in
blood.28 Despite the reported cases of hepatotoxicity and agranulocytosis for
amodiaquine, the lack of new drugs for drug-resistant malaria made it attractive.29
Another important class are the 4-methanoquinolines including mefloquine, halofantrine
and lumifantrine.27 In addition to neuropsychiatric side effects, drug resistance in
southeast asia has limited the use of mefloquine. Halofantrine is another aminoalcohol
effective for treating chloroquine-resistant malaria, but cardiotoxicity is associated with
its use. Lumefantrine is a racemic fluorene derivative which is only available in
coformulation with artemether.29
Primaquine, pamaquine and bulaquine belong to a class of 8-aminoquinolines.27
Primaquine is one of the few drugs effective against both gametocytes of P. falciparum
and hypnozites of P. vivax and P. ovale. However, its short half-life (6 hrs) makes it
contraindicated in patients with G6PD deficiency, because it has to be taken for two
weeks to overcome relapse in P. ovale and vivax infections.28
Artemisinin belongs to a class of sesquiterterpene lactones, extracted from a sweet
woodworm Artemisia annua.29 Artemisinin derivatives such as artemether, artesunate and
arteether have been used recently in China and SE Asia for the management of malaria.
Their high gametocidal effect and low resistance profile made them the mainstay
combination therapy.28 Unfortunately artemisinin can not be used alone due to its short
half-life, and hence the WHO highly recommends administration of ACTs. It has been
9

suggested that these endoperoxides act by damaging Sarco-Endoplasmic Reticulum Ca2+ATPase (SERCA).29

Figure 1.3. Currently available antimalarial drugs
Atovaquone is a hydroxy-naphthoquinone which acts by collapsing mitochondrial
membrane potential of the parasite.27 It’s usually used for treatment and prevention of
chloroquine-resistant P. falciparum in combination with proguanil (Malarone). Proguanil
is a biguanide antifolate that synergistically acts by reducing the concentration of
atovaquone needed.29
Sulfadoxime and pyrimethamine are antifolate inhibitors which inhibit DNA synthesis of
the parasite by specifically targeting dihydropteroate synthase and dihydrofolate
10

reductase enzymes. SP (Fansidar) is very effective when administered in combination
with amodiaquine.29 Dapsone is another sulfone drug used with chlorproguanil (lapdap),
although withdrawn due to its hemolytic toxicity. Antibiotics are also recommended for
use in quinoline-resistant strains. Tetracyclines (tetracycline & doxycycline) and
macrolides (clindamycin & azithromycin) act by inhibiting RNA synthesis. They are very
beneficial in combination therapy with quinine.31
Research and development of new and recycled antimalarial drugs is still in progress, and
many drugs are in their preclinical and clinical phases. 4-aminoquinoline drugs such as
AQ-13 and N-tert-butyl-isoquine (GSK369796) are analogues of chloroquine and
amodiaquine which are in Phase II clinical and Preclinical trials respectively. AQ-13 is
being studied for uncomplicated P. falciparum malaria but there is a concern of cross
resistance with chloroquine.33 N-tert-butyl-isoquine is highly effective and possesses
better overall preclinical safety profile than chloroquine or amodiaquine.34
Tefenoquine and NPC-1161B are 8-aminoquinolines under inverstigation for the
treatment of the hypnozoite stages of P. vivax and P. ovale that are responsible for
relapse of these malaria species. Tefenoquine has an advantage over primaquine in that it
is long acting (2-3 weeks) for treating liver stages of P. vivax. Tafenoquine is currently in
late stage development as an anti-malarial prophylactic agent, and NPC-1161B is in late
preclinical development.35
The disadvantages of semisynthetic artemisinin derivatives are their short half-lives,
dependence on plant source for starting material, and alarming reports of ACT treatment
failures which call for a need for new analogues to this class of antimalarials. OZ277
11

(Arterolane) was the first synthetic ozonide to be evaluated clinically and is now
launched in India in combination with piperaquine, and has obtained regulatory approval
to introduce in seven African countries.
OZ439 is another improved synthetic ozonide candidate designed to provide a singledose oral cure in humans. It has successfully completed Phase I clinical trials and is
currently undergoing Phase IIb trials in malaria patients in combination with piperaquine.
When compared to OZ277 and other former endoperoxides, OZ439 is active against all
asexual erythrocytic stages of P. falciparum and exhibits a substantial increase in the
pharmacokinetic half-life.36
Mutations on dihydrofolate reductase enzyme compromised the efficacy of antifolate
drugs. Research in developing new antifolates such as P65, P218, and WR99210 is inadvance. P218 has proven to potently inhibit both wild-type and clinically relevant
mutated forms of Plasmodium falciparum. Its suitable pharmacologic and safety profile
made it to be an oral antimalarial candidate among this class.37 KAE609 (Cipargamin) is
a first-in-class agent with a new mechanism of action by inhibiting pfATP4 (Ca2+ATPase). This spiroindolone showed a rapid antimalarial activity in phase II clinical trial
for the treatment of uncomplicated P. falciparum and vivax malaria.38
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Figure 1.4. Antimalarial drug candidates in clinical development
1.6. Resistance to Antimalarial Drugs
The plasmodium parasite developed acquired resistance to antimalarial drugs. The type of
the resistance varies with the species, the strain, and the drug used. Many factors account
for the development and spread of resistance including drug-use patterns, characteristics
of the drug, host factors, parasite characteristics, vector, and environmental factors.39
Drug resistance to several novel antimalarial drugs has been reported when used as
monotherapy and combination drugs. Plasmodium falciparum is the main concern and
cause of resistance among the five species. Chloroquine resistance to P. vivax is largely
concentrated in Indonesia and Papua New Guinea. Chloroquine retained adequate
efficacy against P. ovale and P. malariae, but delayed parasite clearance times is
13

observed.40 There are recent reports of treatment failure and clinical resistance to
artemisinin-based therapy in western Cambodia.41

Figure 1.5. Approximate dates of introduction and treatment failure of antimalarial drugs
[Abbreviations: Chloroquine (CQ), Atovaquine-Proguanil (PG), Pyrimethamine (Pyr), Quinine (Q),
Sulfadoxine (SDX), Artimisinin and derivatives (Art), Mefloquine (Mef), Halofantrine (Hal), Atovaquone
(Ato) , LapDap: Chlorproguanil–Dapsone (LD), Resistance (R), Combinations (Comb)]. 42

Genetic mutations in P. falciparum strains have been linked with phenotypes of clinical
resistance and putative markers have emerged and reported.39
Gene
pfcrt
pfmdr 1

Product
Transporter
Transporter

Genetic Determinant
Thr76
Tyr86

Drug
Chloroquine
Chloroquine, mefloquine, quinine,
dihydroartemisinin, artesunate

dhps

Dihydropteroate
Synthetase
Dihydrofolate
Reductase
Cytochrome b

Gly437, Glu540,
Gly581
Asn108, Arg59,
Ile51, Leu164
Ser268

Sulfadoxine

dhfr
cytb

Pyrimethamine
Atovaquone

Table 1.3. Mutations in P. falciparum associated with resistance to antimalarial drugs39
In order to counter drug resistance and delay the emergence of more resistance, many
combination therapies have been adapted. The drugs to be used in combined therapies
might require to have separate mechanisms of action against same stage of the parasite.
Artemisinin derivatives along with other antimalarial classes present effort towards
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achieving such therapeutic level.39 Current combination regimens recommended by the
WHO include artemether-lumefantrine, artesunate-amodiaquine, artesunate-mefloquine,
and artesunate-SP.31
1.7.Reversed Chloroquines
Chloroquine (Resochin) was first synthesized in 1934 by a German chemist, Hans
Andersag, by modifying mepacrine, replacing the acridine ring with a quinoline ring.43
Chloroquine is a weak base containing a side-chain diethylamine nitrogen (pKa = 10.2)
and a quinoline ring nitrogen (pKa = 8.1). It is administered as a racemic mixture of two
enantiomers of which the (+)-CQ enantiomer is more potent against CQ-resistant strains
of P. falciparum than the (-)-chloroquine enantiomer.45 Chloroquine is indicated for
treatment and prevention of acute uncomplicated malaria.47
Chloroquine could be administered in oral, subcutaneous, intramuscular and rectal routes.
When taken orally, CQ is rapidly absorbed from GI tract with bioavailability of 7580 %.45 It has an onset of action of 1-2 hrs and half-life of 3-6 days.45 CQ is metabolized
in liver by CYP3A, CYP2C8, and CYP2D6 enzymes to mono-desethyl CQ (30-40%) and
bisdesethyl CQ (5-10%).45 The CQ side chain is further dealkylated to form 7-chloro-4aminoquinoline. About 70% of the ingested drug is excreted unchanged in urine.45
CQ targets the biochemical pathway in the acidic digestive vacoule (DV) of P.
falciparum. Heme released during metabolism of hemoglobin biocrystallizes to inert
hemozoin by the Plasmodium parasite. CQ accumulates in the DV and blocks heme

15

biocrystallization to hemozoin by forming cytotoxic CQ–heme complexes and other
mechanisms that kill the parasites by making the cell-membrane permeable.46

Figure 1.6. Mechanism of action of CQ and electron micrograph of the DV48
In the DV of Plasmodium falciparum (pH = 5.5), CQ is trapped at high concentration in
its doubly protonated and membrane-impermeable form.47 The CQ-resistant strain
accumulates 4-10 times less CQ than CQ-sensitive strains of P. falciparum, thus the
intracellular CQ concentration will be less toxic to the parasite.46
Chloroquine is effective, cheap, and safe to children and pregnant women. It has been
one of the most successful antimalarials ever developed and used as the most reliable
firstline prophylaxis for 40 years. The first cases of resistance were reported from South
America in 1961. The resistance to CQ is linked to mutation in the DV membrane protein
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of Plasmodium falciparum chloroquine resistant transporter (PfCRT).44 The change from
lysine (K) to threonine (T) in the transmembrane domain of PfCRT appears to be
required for the resistance.49
Parasite type and origin
Chloroquine sensitive
Wild type
106/1 (reverant)
Chloroquine resistant
Southeast Asia & Africa, type E1a
Southeast Asia & Africa, type E1b
Papua New Guinea, type P1
South America, type W1a
South America, type W1b
South America, type W2

PfCRT position and encoded aminoacid
75 76 97 220 271 326 356

72

74

371

C
C

M
I

N
E

K
K

H
H

A
S

Q
E

N
S

I
I

R
I

C
C
S
S
C
C

I
I
M
M
M
M

E
E
N
N
N
E

T
T
T
T
T
T

H
H
H
H
H
Q

S
S
S
S
S
S

E
E
Q
Q
Q
Q

S
S
D
D
D
N

T
I
L
L
L
I

I
I
R
R
R
T

Table 1.4. Mutant forms of PfCRT and association of the K76T marker with chloroquine
resistant P. falciparum from different geographic regions50

Several reversal agents or chemosentisezers that reverse the resistance by inhibiting the
efflux of chloroquine via membrane transporters of the DV of Plasmodium falciparum
resistant strain have been reported. Verapamil and two other calcium channel blockers,
vinblastine and daunomycin, are among the first drugs reported that slowed the release
and increased the accumulation of chloroquine by resistant P. falciparum.52
Subsequently the reversal effect of tricyclic antidepressant, desipramine, and selective
serotonin re-uptake inhibitor (SSRI), fluoxetine, were reported.53, 54 Fluoxetine showed an
increased reversal activity than verapamil when tested against CQ-resistant W2 clone of
P. falciparum.54
Antihistamines such as chlorpheniramine (racemic) and promethazine also showed
reversal of chloroquine resistance in vitro against CQ-resistant P. falciparum.55,56
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Combination of chemosentisizers had also displayed an additive effect in potentiating CQ
accumulation in the DV of the resistant parasite.57 The antimalarial drug, primaquine,
also has a synergic activity with chloroquine and it blocks PfCRT.58 It was implicated by
recent study that the mutant PfCRT uses reversal agents such as verapamil,
chlorpheniramine, desipramine, prometazine, fluoxetine and primaquine as substrates.59

Figure 1.7. Pharmacophore of chloroquine reversal resistance60
Bhattacharjee et al. have developed a pharmacophore for reversal agents.60 The
pharmacophore has a general structure of two aromatic hydrophobic groups and a
hydrogen bond acceptor, preferably at a side chain nitrogen atom. The class of drugs
which qualify for this pharmacophore include calcium channel blockers, antihistamines,
tricyclic antidepressants and selective serotonin reuptake inhibitors (SSRI’s).
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Figure 1.8. Structures of known CQ-resistance reversal agents used as pharmacophores
To circumvent chloroquine resistance, reversed chloroquines were designed in Peyton
lab. These are hybrid drugs comprising quinoline nucleus and reversal agent moiety. In
earlier studies, the tricyclic antidrepressant drug, imipramine, showed the highest potency
when tested for its CQ resistance reversal effect against W2 clone of P. falciparum.

61

The first hybrid molecule, PL01, was synthesized by linking chloroquine moiety and
imipramine as a RA. The hybrid analogue was found to be very effective against both
CQ-sensitive and CQ-resistant strains of P. falciparum when compared to chloroquine.62
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Modifications were made to PL01 to increase the oral availability. As a result a lead
antimalarial drug candidate, PL69, was developed. It was found to be effective for CQresistant malaria in vitro. The IC50 values of PL69 against D6, Dd2, and 7G8 strains of
P. falciparum were 0.9, 1.6, and 1.8 nM, when compared to CQ values of 6.9, 102, and
106 nM. PL69 was also orally available in a mouse model of malaria. In vivo, it cured
mice infected with P. berghei at <64 mg/kg/day, which is equimolar dose with of
chloroquine.63

PL01

PL69

Figure 1.9. The hit (PL01) and the lead (PL69) RCQ’s synthesized in Peyton lab
Moreover, the mechanism of action was indicated to be similar to CQ, by inhibiting the
formation of hemozoin. PL69 (DM1157) is now in late-stage preclinical studies by
DesignMedix. This lead RCQ candidate has physico-chemical features that makes it a
favourable partner drug for antimalarial combination therapy. The drug discovery
research is still on progress to furnish more back-up drugs for the pipeline.64
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CHAPTER 2: Click Chemistry
2.1. Introduction
Nature’s giant molecules are constructed from a small building blocks by few types of
reactions for connecting them together. Biological macromolecules such as
polysaccharides, proteins and nucleic acids are all condensation polymers of small
subunits formed by carbon-heteroatom bonds. Following Mother Nature’s strategy,
Sharpless, Kolb, and Finn identified a group of reactions and developed an approach
called ‘Click Chemistry’ in 2001.65 The main objective of click chemistry was to develop
an array of selective, powerful and modular blocks which are reliable and have wide
application.66
Sharpless and coworkers have set criteria that a process must meet to fulfill these
reactions: “The reaction must be modular, wide in scope, give very high yields, generate
only inoffensive by-products that can be removed by non-cromatographic methods, and
be stereospecific (but not necessarily enantioselective). The required process
characteristics include simple reaction conditions, readily available starting materials
and reagents, the use of no solvents or a solvent that is benign (such as water) or easily
removed, and simple product isolation.’’ 66,67
Finn and Fokin have developed common attributes of click reactions that many click
compounds are derived from alkenes and alkynes, and that the bond is formed between
carbon and heteroatom (mostly N, O & S). In addtion click reactions are strongly
exothermic and are usually either fusion or condensation processes. Moreover, many
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click reactions are highly tolerant of water. In point of fact, they are often accelerated by
the presence of water.68
2.2. Types of click reactions
There are mainly four types of click reactions that use olefins and acetylenes as their
carbon framework for forming carbon-heteroatom bond. These reactions include:
-

Cycloaddition reactions: for example hetero-Diels-Alder and 1,3-dipolar
cycloadditions

-

Nucleophilic ring-opening on strained heterocyclic electrophiles including
epoxides, aziridines, cyclic sulfates & sulfamidates and aziridinium &
episulfonium ions69

-

Non-aldol carbonyl chemistry including formation of oxime ethers, hydrazones
and aromatic heterocycles

-

Addition to carbon–carbon multiple bonds such as epoxidation, dihydroxylation,
aziridination, and nitrosyl and sulfenyl halide additions70

2.3. Huigsen 1,3-Cycloaddition reactions
The potential and the mechanism of 1,3-dipolar cycloaddition reaction between alkynes
and azides to form 1,2,3-triazoles was unveilled by Huisgen et al. in the 1960s.71
However, the reaction was not utilized to its full extent until the copper(I)-catalyzed
Azide-Alkyne cycloaddition (CuAAC) version reaction is discovered.72
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Scheme 2.1. Click Chemistry – energetically highly favorable linking reactions
The potential of this reaction is very high due to the wide range of substituents involving
alkynes and azides. Several triazoles have been made by using the Huigsen 1,3cycloaddition reaction before the advent of catalysed reactions. Pearson et al. described
the synthesis of monosubstituted dihydropyrrolo-1,2,3-triazole analogue of antitumor
dehydropyrrolizidine alkaloid using an intramolecular azide–alkyne cycloaddition, by
refluxing the azide in toluene in 55% yield.73
Nevertheless, this reaction has suffered a lack of selectivity for more than 40 years
because of the weak directing effect of the substituents yielding a mixture of the 1,4- and
the 1,5-regioisomers. Another disadvantage of this reaction is that the formation of
products require long heating and the two regioisomers are challenging to separate using
classical chromatographic procedures.74
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Scheme 2.2. Synthesis of antitumor dehydropyrrolizidine analogue
When the reactants are heated without a catalyst, mixture of 1,4 and 1,5-triazoles are
formed. When the reaction is catalysed by ruthenium, only the 1,5-regioisomer is formed.
This was shown by Imperio et al. on the synthesis of Steganacin and Podophyllotoxun
analogues to replace the lactone ring by 1,5-disubstituted triazole selectively.75 However,
the copper catalysed azide-alkyne cycloaddition (CuAAC) reaction produces only the
1,4-regioisomer.

Scheme 2.3. The 1,3-dipolar cycloaddition between azides and alkynes
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2.4. Copper catalysed Azide-Alkyne cycloaddition
The copper(I)-catalyzed cycloaddition reaction between azides and terminal alkynes to
give 1,4-disubstituted 1,2,3-triazoles has become the benchmark of ‘click chemistry’.
This reaction is very reliable, selective, biocompatible and exhibits a broad scope.76 It
was reported that the copper (I) salts were able to accelerate the reaction by up to 10
million times. 77,80
One of the starting materials, azide, has a unique advantage of stability towards H2O, O2
and other organic synthetic conditions. Azide and alkyne functional groups are not
reactive to other functionalities because of their high kinetic barrier.81 Usually the
reaction proceeds to completion in 6-36 hours at ambient temperature (room temperature
to 500C). The catalyst is prepared in situ by reducing Cu(II) to Cu(I) salts using sodium
ascorbate/ascorbic acid to get a cheaper and purer source. Sodium Ascorbate has proven
to be an excellent reducing agent at 0.25-2% catalyst concentration.
The common solvents used include mixture of tert-butanol/ethanol and water without
using any additional organic solvent. However, when reducing agent is not used,
copper(I) salts including CuI and CuOTf : C6H6 can be used directly by utilizing one
equivalent of nitrogen base (triethyl amine, DIPEA) in a cosolvent (acetonitrile,
tetrahydrofuran, dichloromethane and toluene).77
The CuAAC is a very versatile reaction in that it proceeds best in aqueous systems
including serum and whole blood, over a broad temperature range (0-160°C). Its
remarkably insensitivity to wide range of pH (4 to 12) and stable to redox degredation
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made the reaction to succeed beyond limit in the presence of all functional groups tested
to date. 78

Figure 2.1. Proposed catalytic cycle for the CuAAC reaction
The proposed catalytic mechanism suggests that the 1,3-dipolar cycloaddition of terminal
alkynes and azides is catalyzed by copper(I) salts via the formation of copper−acetylide
complex, followed by a stepwise or concerted addition to an azide. This mechanism
makes the catalysis not to be functional on internal alkynes.80
2.5. Applications of Click Chemistry
Click chemistry is originally developed for assisting medicinal chemists to have a
triumph over combinational chemistry issues. Based on solution-phase library synthesis,
Lexicon Pharmaceuticals synthesised 200,000 compounds of acceptable purity on 25-50
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mg scale using click chemistry. The application of click chemistry is wide ranging from
drug discovery to material science.81
The applicability of click chemistry in bioconjugation involves the attachment of
synthetic labels to biomolecular framework covalently. CC enables lengthy
bioconjugation processes of 60 steps with more than 99.8% yield. The bioorthagonal
properties and solvent tolerance make azides and alkynes very important groups in
bioconjugation.82 The first application of CC in bioconjugation was shown by making
1,4-substituted [1,2,3]-triazoles in peptide backbones.80 Because the presence of copper
in CuAAC may create hinderance to bioorthogonal conjugation in living systems, copperfree click chemistry is applicable using Dibenzcyclooctyl (DBCO) as a source of alkyne.
After introduction of CC, its significance in materials science, specifically in polymer
synthesis, was demonstrated by the synthesis of triazole-based dendrimers. The unique
properties and application made dendrimers to receive much attention. The main problem
in the purification during dendrimer synthesis was solved by the fidelity of CuAAC.83
The first triazole-based dendrimer was synthesiszed by sequential click reactions on bisalkynyl scaffold flexible with an azide anion substitution. The ability of polydentate 1,4disubstituted 1,2,3-triazole ligands to stabilize Cu(I) species under physiologic conditions
has proven vital applicaton in biological systems.84
Click chemistry has shown to have a cutting-edge application in the demanding world of
medicinal chemistry in developing novel approaches to screening compound libraries.
One of the main reason which makes CC reliable in drug discovery is that the compounds
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can be screened directly from the reaction mixture. This was shown in the discovery of
Human r-1,3-fucosyltransferase enzyme when the Cu(I)-catalyzed triazole synthesis was
utilized to create library of GDP (guanosine diphosphate)-triazole candidates as the crude
aqueous reaction were tested directly.85 The other applications of click chemistry include
glycoscience, peptide chemistry, supramolecular chemistry, oligonucleotide synthesis and
others.82
2.6. Click chemistry in Drug discovery
It is a challenging task for medicinal chemists to develop new patentable drugs with
strong activity and good ADMET properties in short time. The triazole-forming Click
chemistry accelerates drug discovery in hit finding and lead optimization due to its
reliance on extremely quick reactions in high yield.
Most of triazole containing drugs available so far are enzyme inhibitors, receptor ligands,
peptides, and modified natural products. There are few drugs available on the market or
in clinical trials
derivative

including anticancer carboxyamidotriazole (CAI), the nucleoside

non-nucloside

reverse

transcriptase

inhibitor

Tert-

butyldimethylsilylspiroaminooxathioledioxide (TSAO), β-lactum antibiotic Tazobactum
and the cephalosporine cefatrizine.76
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Figure 2.2. Drugs based on 1,2,3-triazoles76
Before Click chemistry came into action, several molecules that contain 1,2,3triazole

moiety

anticancer,

were

antibacterial,

synthesized

using

antimalarial,

various

antifungal,

methods.

These

antitubercular,

include
antiviral,

antihypertensive, and hypocholesterolemic agents.76
Pisaneschi et al. synthesized 3-cyanoquinoline-based fluorinated compounds that would
make a good imaging agent for epidermal growth factor receptor (EGFR) to facilitate the
clinical evaluation of tumors. One of the 20-fluoroethyl-1,2,3-triazoles showed to have
good cellular potency, low lipophilicity and good metabolic stability in vitro to be a
promising radiotracer for imaging of EGFR status.86 Another new class C5- curcuminoid4-aminoquinoline molecular hybrids has shown potential anticancer activity when tested
on 60 human cancer cell lines at nM concentration.87
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Pisaneschi et al.

Rawat et al.

Figure 2.3. Triazole based anticancer molecules
The application of Click chemistry of 1,2,3-triazoles in synthesizing new class of
antifungal and antimicrobial agents is becoming prevalent.76 A series of substituted
triazoles were synthesized using 1,2,3-triazole containing quinoline moiety and tested for
their antimicrobial and antifungal activity. SAR investigation revealed that the nature of
the substituent on the 4-position of the triazole ring influences the antimicrobial activity.
When evaluated for in vitro activity and compared with standard antifungal Cyclopiroxolamine, the 3-methylthien-2-yl moiety showed a broad spectrum antimicrobial
activity against all tested strains.88
Two substituted 1,2,3-triazoles containing quinoline moiety showed good antibacterial
and moderate antifungal activity, particularly the compounds with 3-methyl thienyl
substituents are found to have increased antimicrobial activity.89 In other study, Thomas
and co-workers reported in vitro activity of similar antibacterials and antifungals. The
compounds demonstrated moderate to very good activities, when comparable to
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Ciprofloxacin and Ciclopiroxolamine respectively. The enhanced activity is due to the
presence of active piperazine and its derivatives in their structures.90

Sumangala et al

Holla et al

Thomas et al

Figure 2.4. Triazole based antibacterial and antifungal molecules
Olomola et al synthesized anti-HIV triazole-based hybrids using Cu(I)-catalysed
cycloaddition reaction by combining 3-alkynylmethylcoumarins with azidothymidine
(AZT). The structurally complex coumarin-AZT conjugates have the potential dualaction as HIV-1 protease and non-nucleoside reverse transcriptase inhibitors.91

Figure 2.5. Triazole based anti-HIV hybrid molecule
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2.7. Triazole based Antimalarials
The modification of well-established antimalarials, particularly chloroquine is very
common in making new drugs to counteract drug resistance. Different groups reported
the synthesis of 1,2,3-triazole based quinoline moieties using copper(I)-catalysed
cycloaddition click chemistry.
A series of 4-aminoquinoline-1,2-3-triazole based hybrids were synthesized and
evaluated for their in vitro antimalarial acivity against D6 and W2 strains of P.
falciparum. Some of the compounds have shown promising antimalarial activity without
showing any toxicity against Vero cells.92 On the similar studies done by Mamgain et al.,
the absence of linear alkyl chain linker have shown to diminish the antimalarial activity.93
Pereira et al directly clicked 7-chloroquinoline with different substituents in position C4
of the quinoline at the N1 of the triazole ring. When evaluated for their in vitro activity
against P. falciparum (W2), the compounds showed moderate antimalarial activity and
low cytotoxicity to Hep G2A16 cells. The decreased activity was explained by the low
resonance contribution of the triazole ring to stabilize the acidic form of the quinoline
ring that decreases the pKa of the quinoline nitrogen.94
Another set of triazole molecules was made by the Blackie group using the mefloquine
pharamacophore by CuAAC chemistry. The in vitro biological activity of the compounds
on NF54 chloroquine-sensitive strain of Plasmodium falciparum was determined to be in
the lower l.0 uM range. The authors concluded that the inclusion of the piperazine does
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not appear to be advantageous in biological activity because the single basic nitrogen in
the side chain seemed to provide sufficient basicity to maintain activity.95

Figure 2.6. Triazole based antimalarials
Many hybrid drugs were synthesized by combining 7-chloroquinoline moiety with other
drugs. The synthesis and antimalarial activities of 1H-1,2,3-triazole tethered 7chloroquinoline-Isatin hybrids was shown by Raj and others. The compound with three
carbon alkyl chain and chloro substituent at the C-5 position of the isatin ring displayed
the best activity against cultured W2 strain among the test compounds.96
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1,2,3-Triazole tethered β-lactam and 7-chloroquinoline bifunctional hybrids were
synthesized and evaluated against W2 strain of P. falciparum for their antimalarial
activities. The activity was found to be dependent on the N-substituent of the β-lactam
ring and the bis-triazole at the C-3 position, and the p-fluorophenyl substituted analogue
showed maximum activity. Docking studies via inhibiting P. falciparum dihydofolate
reductase (PfDHFR) enzyme was made to explain the activity.97
Other

non-quinoline

based

antimalarial

compounds

having

1,2,3-triazole

pharamacophore were made using click chemistry. Triazole-based β-lactams were
synthesized and evaluated for their antiplasmodial activity against 3D7, K1, and W2
strains of Plasmodium falciparum, and KB cells for their cytotoxicity profiles. The
compound with an N-cyclohexyl substituent in the β-lactam ring and a phenyl group on
the triazole showed better antiplasmodial activity and cytotoxicity.98
2.8. Triazoles as Pharmacophores, Bioisosters and Linkers
The importance of triazolic compounds in medicinal chemistry is undeniable. There are
three main groups of 1,2,3- triazoles: monocyclic, benzotriazoles and 1,2,3-triazolium
salts. Based on the position of the substituent, the monocyclic 1,2,3- triazoles are
subdivided into 1H-, 2H- and 4H-1,2,3-triazoles. The 1H- and 2H- forms are tautomers in
equilibrium both in solution and gas phase. The 1H-1,2,3-triazole acts as both weak base
(pKa = 1.17) and weak acid (pKa = 9.4), and the ring is not protonated at physiological
pH.76, 99
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The acidity and basicity of nitrogen atoms in 1,2,3-triazoles is explained well by their
resemblance of having both pyrrole and pyridine-like electronic properties respectively.
The pyridine-type nitrogen is weakly σ-donating and strongly π-accepting while the fivemembered pyrrole offers an amine-like nitrogen which makes it σ-accepting and πdonating, causing an aromatic system of π-electron excess.100

Figure 2.7. Electronic structure of 1H-1,2,3-triazole
The 1,2,3-triazole ring exhibits three resonance forms at which the three N-atoms cause
the aromatic π-system to be very polarized on a σ-framework. When both resonance and
inductive effect are assessed, the two C-atoms and the N-atom in the 1-position showed
positive charges, where as the 2- and 3-Nitrogen atoms indicated partial negative charges.
The experimental and computational data showed to be consistent indicating a very large
dipole moment of 4.38 and 4.55 D respectively.100

Figure 2.8. Structures, tautomerism, partial charges & dipole moments of the 1H-1,2,3-triazole
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Although the incorporation of 1,2,3-triazoles into pharmacologically active molecules
had been started decades ago, it became more popular after the introduction of coppercatalyzed click chemistry. The triazole group not only functiones as a passive linker but
also as a key part of the pharmacophore. The stabilty to acid-base hydrolysis, oxidativereductive conditions and resistance to metabolic degradation make triazoles excellent
candidates as pharmacophores. Moreover, these heterocycles readily associate with
biological targets via H-bonding and dipole–dipole interactions.74, 76, 101
According to the arenology principles, triazoles have been employed to substitute labile
functional groups such as amides and esters to generate functional, nonclassical
bioisosteres.102 Due to the wide application of peptide chemistry, the bioisosteric
replacement of amide bonds with triazole ring is becoming an interest. Depending on the
substituent pattern of the triazole, disubstituted 1,2,3-triazoles can replace either trans- or
cis-configuration of the amide bond. The presence of both hydrogen bond donor and
acceptor at similar positions, and closely related dipole moment make 1,2,3-triazloes
ideal bioisosters for amides.103

Figure 2.9. Disubstituted trans-amides and 1,2,3-triazoles as bioisosteres102

36

The ability to function as rigid linking units makes 1,2,3-triazoles to be extremely stable
to hydrolysis and an excellent replacement for amides. Phillips et al. have replaced the
amide group of Linezolid, an oxazolidinone antibiotic, with a 1,2,3-triazole ring and
showed the retention of antibacterial activity.104 In other similar work, 1,2,3-triazolecontaining novobiocin analogs were designed and synthesized by replacing the amide
moiety. The analogues exhibited comparable antiproliferative activity when evaluated
against two breast cancer cell lines.105

Figure 2.10. 1,2,3-Triazoles used as bioisosters of trans-amides
The triazole moiety has also been shown to act as a non-classical bioisostere of an ester
group in arecoline, a muscarinic agonist, for the treatment of Alzheimer’s disease.106
Because of the basic aromacity of 1,2,3-triazoles, they are suitable isosters of
heteroaromatic rings. In addition, the triazole moiety is also shown to be the isostere of
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double bond. In addition to their pharmacophore role, triazoles have been used as
favorable linkers in the synthesis of dimers and bidentate inhibitors.107
In order to address the challenges of high costs associated with high-throughput screening
and chemical synthesis, Durrant and McCammon developed a novel computer algorithm,
called AutoClickChem, capable of performing many click chemistry reactions in silico
that may prove useful in rational drug design and optimization. AutoClickChem, which
combines virtual screening and click chemistry, is based on the pymolecule toolbox, a
framework that facilitates the development of future python-based programs requiring
molecular model manipulation.108
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CHAPTER 3: Synthesis of 1,2,3-Triazole-based Antimalarials
Series of click compounds were synthesized via copper(I)-catalyzed alkyne-azide
cycloaddition reaction using sodium ascorbate as a reducing agent. Based on previous
work done in Peyton and other labs, three aliphatic linear chains as linker was considered
as optimum length both interms of antimalarial activity and hydrophilicity. 63
3.1. First-Generation Click Compounds
The azide analogue was prepared in three steps with very good yields as outlined in
Scheme 3.1. First, the amino-alcohol quinoline (PL16) was synthesized by nucleophilic
aromatic substitution of commercially available starting material 4,7-dichloroquinoline
with excess aliphatic chain aminoalcohol. The hydroxyl group was mesylated by
methane-sulfonyl chloride and triethylamine base to give mesylated-quinoline (PL29).62
Finally, the azide analogue (PL409) was prepared by nucleophilic acidification using
sodium azide in DMF.109

Scheme 3.1. Synthesis of starting material – azide analogue
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The first seven click compounds were synthesized by reacting the azide analogue
(PL409), which was prepared in large scale, with commercially available terminal
alkynes to give 1,4-disubstituted-1,2,3-triazoles. The method used by Mahohar et al. was
adapted by using copper sulfate pentahydrate as catalyst and, two-fold excess of sodium
ascorbate to reduce the copper (II) to (I).110 An equimolar ratio of tert-butanol and water
was used as mixture of solvents. The reactions were run from room temperature with
maximum temperature reaching 50oC for 3-4 hours to yield the final target compounds in
moderate yield (26 – 76%).

Scheme 3.2. General synthetic pathway of the first generation click compounds
Several substituted terminal alkynes were used as the source of various functional groups.
Tri-substituted terminal alkyne with two aromatic groups and a hydroxyl group was of
particular interest, due to the similarity with the typical pharmacophore of reversal
agents. In addition, both ortho- and meta-methoxy substituted click compounds were
synthesized to make a further structure-activity analysis. In order to evaluate the strength
of electron-withdrawing groups, monofluoro- and difluoro-substituted click compounds
were prepared. Finally, one of the carbons at ortho position of the phenyl group was
replaced by nitrogen and the substituted phenyl groups were replaced by a benzyl group.
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PL No.

Structure of the substituent (R)

% yield

PL404

41

PL405

72

PL406

51

PL407

26

PL408

76

PL412

46

PL414

45

Table 3.1. The first synthesized click compounds
3.2. Para-Phenyl Substituted Triazoles
Based on previous compounds synthesized in the Peyton lab by Bornface Gunsaru et al.,
the para-substituted quinoline analogues showed better activity than their ortho- and
meta-substituted counterparts.111 Various commercially available p-phenyl substituted
terminal alkynes were used to synthesize 10 click compounds using the same synthetic
pathway in low to excellent yield (30 – 95%).
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Scheme 3.3. General synthetic pathway of para-substituted click compounds
PL No.

Substituent at para position

% yield

PL403

OCF3

30

PL411

H

50

PL413

CH3

56

PL415

NH2

72

PL416

Br

69

PL417

OCH3

51

PL418

Cl

76

PL419

CF3

68

PL420

F

84

PL421

NO2

95

Table 3.2. Para-substituted click compounds
In order to perform structure-activity relationship studies, several click compounds
containing electron-donating and electron-withdrawing groups were synthesized.
Unsubstituted (H-substituted) analogue was used as a reference. The p-hydroxy phenyl
substitution was not synthesized because the starting material was not readily available.
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Three electron-donating containing analogues, including amino-, methoxy- ,and methyl
were

synthesized.

In

addition,

electron-withdrawing

groups

such

as

nitro-,

trifluoromethyl-, and the halogens were prepared for comparison. The halogens used was
fluorine, chlorine, and bromine (but not iodine). This is because the p-iodo substituted
terminal alkyne was not commercially available. Finally, a very interesting long-range
electron withdrawing substituent, trifluoromethoxy group, was prepared to compare with
the methoxy and trifluoromethyl groups.112
3.3. Triazole with Reversal Agent Pharmacophore
One additional click compound (PL423) which contains two aromatic rings and nitrogen
atom between the triazole and the aromatic rings was made to associate the activity with
the reversal agent pharmacophore. First the terminal alkyne (PL422) was synthesized
using the Finkelstein reaction by replacing bromine with a better leaving group, iodine.113
The benzhydrylamine was treated by propargyl bromide using catalytic amount of
sodium iodide in diethyl-ether with minimum heating and fair yield. The synthesized
terminal alkyne was reacted with the azide analogue (PL409) under the same condition
with the primarily synthesized click compounds to give PL423 in a good yield.
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Scheme 3.4. Synthesis of PL423
The first series of 18 click compounds was assessed for their antimalarial activity, and six
of them showed better activity than chloroquine against resistant strains of P. falciparum
(Dd2 and 7G8). Additional compounds containing piperazine ring between the triazole
and the aromatic rings were planned to be synthesized in order to incorporate a
protonable nitrogen that possesses a weakly basic character.
3.4. Para-Phenyl Substituted Terminal Alkynes
With the intention of making piperazine containing triazoles, 10 para-substituted
piperazinyl terminal alkynes were prepared. These intermediate molecules were made by
reacting equimolar ratio of readily available p-substituted piperazines with propargyl
bromide.114 The reaction mixture was refluxed overnight using potassium carbonate as a
base and acetonitrile as a solvent with moderate to excellent yields.
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Scheme 3.5. Synthesis of p-phenyl piperazinyl substituted terminal alkynes
PL No.

Structures (R)

% Yield

PL428

32

PL429

87

PL430

98

PL431

70

PL432

95

PL433

69

PL434

57

PL435

67

PL436

86

PL437

94

Table 3.3. Structures of 10 piperazine-containing terminal alkynes
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3.5. Piperazinyl-linked Triazoles
The p-substituted piperazines were selected based on different functional groups,
heteroatomic replacement, linker length between the piperazine and the aromatic ring,
and multiple substitution. The cyclohexyl piperazine was selected for comparison of the
aliphatic cyclic compound with the phenyl-substituted piperazine. Consequently, nine
very interesting piperazinyl containing triazoles were synthesized using CuAAC.
The concentrations of the copper sulphate catalyst and reducing agent sodium ascorbate
were reduced by half from the previous method. This was because of the difficulty in
solubility encountered during the work-up (liquid-liquid extraction) and purification
(recrystallization) processes of the first series of synthesized molecules.96,

114

The

increased reaction time was the cost of reducing the catalyst and reducing agent
concentrations which increased from 3-4 hours to 1-2 days. The amount of tert-butanol
solvent used was also increased to threefold of the water co-solvent with moderately
heating the reaction to 50o C.

Scheme 3.6. Synthesis of piperazine containing triazoles
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The triazole-based synthesized compounds contain both electron-donating (methyl,
methoxy, and hydroxyl) and electron-withdrawing (trifluoromethyl, chloro, and
dichloro). The carbon atom at the ortho position of the phenyl group was mono- and disubstituted by nitrogen to give 2-pyridyl and 2,6-pyrimidyl substituted triazoles.
PL No.

Structures (R)

% Yield

PL440

69

PL441

52

PL442

35

PL443

61

PL444

76

PL445

70

PL446

68

PL447

80

PL448

77

Table 3.4. Structures of piperazinyl-triazoles
The p-trifluoromethyl substituent was made with one aliphatic linker between the
piperazine and the aromatic ring. The unsubstituted (H-substituted) phenyl analogue was
considered as an optimum reference between electron-donating and withdrawing groups.
The di-chloro substituted triazole was also synthesized to notice the change it brings in
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the strengh of the electron-withdrawing capacity of the ring. The click compound
containing cyclohexyl substituent was not successful in synthesizing.
3.6. Triazole-based Bisquinoline Antimalarial

Scheme 3.7. Synthesis of bisquinoline containing triazole
As the potent antimalarial activity of bisquinolines was observed in the previously
synthesized compounds in Peyton lab, bisquinoline containing 1,2,3-triazole ring was
synthesized by copper catalyzed click chemistry (Scheme 3.7).
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The target bisquinoline was synthesized in three steps with moderate to very good yields.
4-piperazinyl-quinoline (PL49) was first synthesized by refluxing commercially available
starting material 4,7-dichloroquinoline with anhydrous piperazine in ethanol.115 The
terminal alkyne analogue (PL467) was then prepared by reacting PL49 with propargyl
bromide using potassium carbonate as a base and acetonitrile as solvent.114 Finally, the
target bisquinoline triazole (PL456) was made by copper catalysed click reaction in
optimum catalytic concentration and reaction time than previous click reactions.
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CHAPTER 4: Structure-Activity Relationship of Triazoles-Based Antimalarials
The efficiency of synthesizing several triazole-based antimalarials have proven click
chemistry to be a fast and efficient route. Antimalarial click compounds were synthesized
using copper(I)-catalyzed azide-alkyne cycloaddition reactions and tested for their in
vitro activity against D6, Dd2, and 7G8 strains of Plasmodium falciparum. Several of
them have shown better activity against chloroquine-resistant strains (Dd2 and 7G8) than
chloroquine.
4.1. The first generation click compounds
The first generation click compounds synthesized in Peyton lab contain the triazole ring
connected directly to one or two aromatic rings with different substitutions. Six of the
triazole-based click compunds showed better activity against chloroquine resistant, Dd2
and 7G8, strains of P. falciparum.
Structure-activity relationship studies were made on the synthesized compounds. The
phenyl-substituted triazole (PL411) showed an enhanced activity when compared to the
2-pyridyl substituted triazole (PL412) against all the three strains. PL411 gave a better
IC50 values of 76.8, 87.5 and 151 nM when compared to 420, 960, and 590 nM (d6, Dd2,
and 7G8 strains respectively) of PL412.
In another comparison, PL411 showed decreased activity which compared to PL414
which has an additional methyl linker between the phenyl and the triazole rings. Thus
addition of a methyl linker was found to be an advantage over direct connection in this
case.
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Figure 4.1. The effect of hetroatomic replacement and linker addition
PL No. Number of Type of
linker (n)
atom (Y)

IC50 (nM)
D6

Dd2

7G8

PL411

0

C

76.8

87.5

151

PL412

0

N

423

696

592

PL414

1

C

9.6

77.7

85.8

Table 4.1. The IC50 comparison of phenyl, 2-pyridyl, and benzyl triazoles
The effect of ortho-, meta-, and para-substitutions were also investigated by comparing
the electron-donating methoxy group on the phenyl directly connected to the triazole
ring. The para-methoxy substituted triazole (PL417) showed an enhanced activity when
compared to the meta-substituted (PL406), which inturn also showed a better activity
than the ortho-substituted triazole (PL405) against all the three strains.

Figure 4.2. The effect of methoxy group substitution
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PL No.

Position of methoxy
substituent

IC50 (nM)
D6

Dd2

7G8

PL405

ortho-

98.6

209.8

192.4

PL406

meta-

52.4

120

122.3

PL417

para-

40.5

108.8

140.1

Table 4.2. The IC50 comparison of ortho-, meta-, and para-methoxy substitutions
The electron-withdrawing strength effect of halogens were compared by mono- and difluorinated substitutions on the phenyl ring directly attached to the triazole. It was found
that double halogen (fluorine) substitution (PL408) had improved activity by, almost 2.5
times, for both D6 and Dd2 strains, when compared to mono-fluoro substitution (PL407).

PL407 (81D6, 109Dd2, 1297G8)

PL408 (23D6, 39Dd2, 967G8)

Figure 4.3. The effect of mono- and di-fluoro substitution

The long-range electro-withdrawing group, the trifluoromethoxy-substituted triazole
(PL403) showed the highest activity among all the 18 synthesized first generation
triazoles. It showed about 4 times better activity than chloroquine against both CQ-

52

resistant strains. The IC50 values of PL403 are 12.8 and 14.5 nM, while CQ has 54 and 63
for Dd2 and 7G8 strains of P. falciparum respectively.
When the para-methoxy substituted triazole (PL417) was compared with PL403, the
latter showed a superior activity. The replacement of hydrogen atoms by the most
electronegative element fluorine presented an 8 times increase in activity. Moreover,
PL403 indicated about 2.5 times increase in activity for Dd2 strain, when compared with
a similar electron-withdrawing substituent, trifluoromethyl-substituted triazole (PL419).

PL417 (41D6, 109Dd2, 1407G8)

PL403 (10D6, 13Dd2, 157G8)

PL419 (11D6, 32Dd2, 197G8)

Figure 4.4. Comparison of the IC50 values of para-methoxy, trifluoromethoxy and
Trifluoromethyl-phenyl substituted click compounds

The electron-donating substituents showed inferior activities than chloroquine. These
include the para-phenyl substitutions of methyl (PL413), amino (PL415), and methoxy
(PL417) functional groups. While the para-methyl substituted triazole presented the best
activity from the three electron donating groups, the para-amino showed the least activity
against all CQ-sensitive and CQ-resistant strains of P. falciparum.
However, the electron-withdrawing groups such as the trifluoromethyl, nitro and the
halogens presented better or comparable activity than chloroquine. Most of them
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exhibited an improved IC50 values than CQ against both resistant strains except the parafluoro substituted triazole (PL420).

PL419 (11D6, 32Dd2, 197G8)

PL421 (19D6, 51Dd2, 457G8)

Figure 4.5. The IC50 values of para-phenyl substituted electron-withdrawing groups
When the halogens are compared, the para-bromophenyl substituted triazole (PL416)
showed the best activity against Dd2 strain of P. falciparum (IC50 of 30.7 nM). The
chloro-substituted (PL418) exhibited enhanced activity against both D6 and 7G8 strains
(IC50 of 18.8 and 36.6 nM respectively) than PL416 and the fluoro-substituted triazole
(PL420). The general trend for the halogens indicated that the antimalarial activity
increases when electronegativity of the substituent atom decreases.

PL416 (423D6, 31Dd2, 507G8)

PL418 (19D6, 43Dd2, 377G8)

PL420 (40D6, 85Dd2, 807G8)

Figure 4.6. The IC50 values comparison of para-halogen substituted triazoles
When all the para-phenyl substituted electron-withdrawing groups are compared, the
trifluoromethyl and the chloro substitutions showed potent activities, with trifluoromethyl
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group possessing the highest. The bromo and nitro groups at para position of the phenyl
ring indicated moderate activities, with the bromo group retaining the maximum activity
of all against Dd2 strain of P. falciparum. The least leaving group, fluorine-substitution,
showed the minimum activity of all electron-withdrawing groups.
Strains of Plasmodium falciparum

Electron-withdrawing group

D6

Br < F < NO2 = Cl < CF3

Dd2

F < NO2 < Cl < CF3 < Br

7G8

F < Br < NO2 < Cl < CF3

Table 4.3. Comparison of various electron-withdrawing groups
Surprisingly, the two click compounds that contain two aromatic groups resembling the
RA pharmacophore showed poor antimalarial activity. The first compound (PL404)
which has a tetra-substituted carbon connecting the triazole ring with two aromatic rings
and hydroxyl group, showed better activity only against 7G8 strain of P. falciparum. The
second click compound (PL423) containing a secondary amine between the triazole and
two aromatic rings showed poor antimalarial activity against all the strains.

PL404 (25D6, 82Dd2, 487G8)

PL423 (80D6, 160Dd2, 1897G8)

Figure 4.7. Click compounds containing pharmacophore similar to the reversal agent
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Out of the 18 synthesized first generation click compounds, six were found to be more
active than chloroquine against CQ-resistant strains of P. falciparum. Although none
showed better activity against the CQ-sensitive (D6) strain, the trifluoromethoxy (PL403)
and trifluoromethyl (PL419) substituted triazoles showed comparable activity with
chloroquine (IC50 values of 10.4 and 11 nM respectively).
All six selected compounds have exhibited better activity against Dd2 strain of P.
falciparum than chloroquine. For the 7G8 strain, five showed an enhanced activity than
CQ except the difluoro-phenyl substituted triazole (PL408), which has an IC50 value of
95.7 nM when compared to 57 nM of CQ (Refer to Table 4.4).
In conclusion, electron-withdrawing (PL416, PL418, PL419, and PL421) and long-range
electron-withdrawing (PL403) substitutions at para positions, and double electron withdrawing (PL408) substitutions were found to be an advantage to have a better
antimalarial activity for these group of click compounds.
4.2. Piperazinyl-linked click compounds
“Second generation” of triazole antimalarials were synthesized by incorporating
piperazine ring between the triazole and the para-substituted phenyl ring, to yield a
protonable nitrogen in the linker which increases the basicity of the molecule. When
compared to the first synthesized click compounds, these 9 compounds generally showed
enhanced antimalarial activity against all the strains of P. falciparum.
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PL No.

Structures

CQ

Chloroquine

IC50 Values
D6 Dd2 7G8
5.9
54
57

PL403

10.4

12.8

14.5

PL408

22.7

39.1

95.7

PL416

423

30.7

49.6

PL418

18.8

42.7

36.6

PL419

11

31.6

18.7

PL421

18.8

50.5

44.5

Table 4.4. Selected first generation click compounds with better activity than CQ
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The para-substituted electro-donating groups generally demonstrated better activities than
CQ and the first generation triazoles with similar substituents. The para-methyl (PL442)
and para-methoxy (PL444) substituted triazoles exhibited an improved activity against
Dd2 and 7G8 strains of P. falciparum than did CQ. However, the para-hydroxy
substituted triazole (PL446) showed poor activity against all the 3 strains of P.
falciparum.

PL442 (12D6, 37Dd2, 187G8)

PL444 (33D6, 68Dd2, 657G8)

PL446 (155D6, 94Dd2, >2507G8)

Figure 4.8. The activity of electron-donating groups substituted at the para position
The 2-pyridyl (PL443) and 2,6-pyrimidyl (PL440) Piperizenyl-substituted triazoles gave
poor activity against all the three strains of P. falciparum when compared to CQ, with
PL440 presenting the lowest activity of all the synthesized triazoles.
As the effect of double substitution of electron-withdrawing groups was shown to
improve the antimalarial activity in the first series of compounds using fluorine; the same
result was obtained with the piperazinyl-linked triazoles. When the dichloro-substituted
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(PL448) was compared with monochloro-substituted (PL447) phenyl-piperazinyl triazole,
the former showing about 1.6 times increased activity against all the three stains.

PL447 (8.8D6, 26.5Dd2, 197G8)

PL448 (6.8D6, 15.2Dd2, 117G8)

Figure 4.9. The comparison of IC50 values of mono and dichloro-substituted triazoles
The addition of a single methyl linker between the piperazine and the phenyl ring have
shown to retain the antimalarial activity against all the three strains of P. falciparum
when the phenyl ring was para-substituted by a trifluoromethyl group.

Figure 4.10. Triazole having methyl linker between piperazine and phenyl rings
Improved antimalarial activity was observed when the first series of triazoles were
compared with piperazine linked for the same substituents. This increase in activity is
attributed to the integration of the piperazine linker, which provides additional proton for
this second generation click triazoles.
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R = CH3,

PL413 (41D6, 61Dd2, 607G8)

PL442 (12D6, 37Dd2, 187G8)

R = CH3O,

PL417 (41D6, 109Dd2, 1407G8)

PL444 (33D6, 68Dd2, 657G8)

R = H,

PL411 (77D6, 88Dd2, 1517G8)

PL445 (17D6, 67Dd2, 747G8)

R = Cl,

PL418 (19D6, 43Dd2, 377G8)

PL447 (8.8D6, 26.5Dd2, 197G8)

Figure 4.11. The comparison of the selected first and second generation triazoles for
similar substituents
When the electron-donating substituents, methyl and methoxy, were compared, PL442
and PL444 indicated more potency than their respective piperazine omitted counterparts
PL413 and PL417 against D6, Dd2 and 7G8 strains. Moreover, PL447, which has an
electron-withdrawing chloro-substituent, indicated two-fold activity when compared to
PL418. The same trend was observed for the unsubstituted (H-substituted) triazoles
against all the three strains (PL411 vs PL445).
In summary, six of the nine synthesized piperazinyl-linked triazoles were found to have
more potent activity than chloroquine against CQ-resistant strains of P. falciparum.
Although none of them showed better activity against CQ-sensitive strain, the para-chloro
(PL447) and dichloro (PL448) substituted click compounds exhibited comparable activity
with chloroquine with an IC50 values of 8.8 and 6.8 nM respectively (Refer to table 4.5).
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PL No.

Structures

IC50 Values
D6

Dd2

7G8

CQ

5

69

47

PL441

10

40

16

PL442

12

37

18

PL444

33

68

65

PL445

17

67

74

PL447

8.8

26.5

19

PL448

6.8

15.2

11

Table 4.5. Selected piperazine containing click compounds having better activity than
Chloroquine against CQ-resistant strains
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All the six selected compounds possessed better potency against Dd2 strain of P.
falciparum than chloroquine. When tested against 7G8 strain, PL441, PL442, PL447 and
PL448 showed enhanced activity but not the para-methoxy (PL444) and the unsubstituted
(PL445) triazoles. Generally, the para and di-substitutions with electron-withdrawing
groups were found to be beneficial for having better antimalarial activity for these types
of piperazine-linked click compounds. PL448 has proved to possess the best activity from
all the second generation triazoles.
4.3. The Activity of Triazole-based Bisquinoline
The triazole-based bisquinoline, PL456, synthesized by linking two chloroquinoline
moieties by triazole ring, was tested for in vitro antimalarial activity against all the three
strains of P. falciparum. Unlike the other click compounds, it showed excellent activity
against CQ-sensitive strain (D6). In addition, PL456 exhibited a potent activity against
both CQ-resistant strains (Dd2 and 7G8) when compared to chloroquine.

Compounds

IC50 (nM)
D6

Dd2

7G8

Chloroquine

9

143

127

PL456

0.5

10

11

Table 4.6. The structure and activity of triazole-based bisquinoline
62

CHAPTER 5: Reversed Chloroquines
5.1. The 6-Aminoquinoline antimalarials
Although the 4- and 8-quinoline substitutions are very common on the quinoline ring,
there are few antimalarials containing functional groups on the 6-position. An electrondonating, methoxy group, is a very common substituent on the 6-position of the quinoline
ring. Common antimalarial drugs such as quinine and primaquine all have a methoxy
functional group substitution on the 6-position but the main linkers are on the 4- and 8quinoline substitutions respectively.

Scheme 5.1. Synthesis of 6-aminoquinoline antimalarial, PL370
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A reversed quinoline hybrid molecule was synthesized in Peyton lab by linking 6quinoline

moiety

with

benzhydryl-piperazine

which

has

the

reversal

agent

pharmacophore. First, PL323 was prepared by treating 6-aminoquinoline with 3chloropropionyl-chloride in a cold reaction using triethylamine as a base and
dichloromethane as a solvent.116 The amide was reacted with benzhydryl-piperazine to
form PL369, which is further reduced using LiAlH4 in cold reaction to get the target
molecule, PL370 in a good yield.
When tested for antimalarial activity against D6, Dd2 and 7G8 strains of P. falciparum,
PL370 showed poor antimalarial activty against both CQ-sensitive and CQ-resistant
strains with an IC50 value of >250 nm when compared to chloroquine.
5.2. Fluoxetine as Reversal Agent
Among the common reversal agents, the SSRI antidepresant, fluoxetine which doesn’t
possess any intrinsic antimalarial activity when used alone, showed to potentiate the
effect of chloroquine. Fluoxetine showed to modulate chloroquine resistance of CQresistant W2 clone by 66% at a concentrations of 500 nM with verapamil showing only
61%.54 In other recent studies, fluoxetine showed to reverse both chloroquine and
mefloquine resistance against Dd2 strain of P. falciparum although it indicated to be
more synergistic with chloroquine than mefloquine.117
In addition, fluoxetine has proven to be a highly effective chemosensitizer in multidrug
resistance (MDR) for cancer chemotherapy. In vitro, fluoxetine enhanced 10-100 fold
cytotoxicity of many anticancer drugs in drug-resistant cells by increasing drug
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accumulation within MDR-cells and inhibiting drug efflux from those cells. In vivo,
fluoxetine enhanced 12-fold accumulation of doxorubicin within tumors with unaltered
pharmacokinetics.118
In other in vitro and in vivo findings, fluoxetine was found to be a chemosensitizer of the
multipump type and considered as a fourth-generation chemosensitizer.119 Considering
the effect of fluoxetine as a better chemosentisizer, reversed chloroquine molecule using
fluoxetine as a reversal agent was synthesized in Peyton lab.
The free-base was reacted with PL29 using triethylamine as a base in tetrahydrofuran to
give PL410 in moderate yield. The molecule was potent antimalarial and showed about
20-fold activity when compared to chloroquine. It has an IC50 values of < 2.5 nm for Dd2
and 7G8 strains of P. falciparum while CQ has 54 and 57 nM respectively.

Scheme 5.2. Synthesis of reversed chloroquine using fluoxetine as reversal agent
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5.3. Meta-substituted Analogue of PL69
The first hit compound, PL01 which was synthesized as a hybrid drug by using
haloquinoline moiety and imipramine as a reversal agent was optimized to increase its
hydrophilicity. PL69 was the result of lead optimization that is both potent antimalarial
and has better hydrophilicity than the first analogue. In order to see the effect of a
substituent on the activity, PL425, which has the nitrogens on the meta positions of the
aromatic rings of the reversal agent instead of on the ortho positions was synthesized.
First, 1,8-Diazafluoren-9-one (DFO) was reacted with protected piperidine (Ethyl-4amino-1-piperidine carboxylate) by using catalytic amount of p-toluenesulfonic acid to

Scheme 5.3. Synthesis of m-substituted analogue of PL69
form PL460 in an excellent yield. The piperidine was deprotected in basic condition by
treating with NaOH in ethanol to prepare the intermediate product PL424. Finally, the
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reversal agent was reacted with PL29 using potassium carbonate base to give the target
compound, PL425 in a good yield.
The meta-substituted compound showed better antimalarial activity than CQ, only against
Dd2 strain of P. falciparum with an IC50 value 32.5 nM when compared to 54 nM of
chloroquine. However, for the D6 and 7G8 strains, PL425 was found to be less active
than CQ.
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CHAPTER 6: Summary and Conclusion
Malaria is considered as one of the most prevalent and debilitating diseases affecting
humans. There are 3.4 billion people at risk of malaria transmission with more than half a
million deaths, many of them are children. Plasmodium falciparum is the most virulent
form and responsible for about 80% of human malaria worldwide. The plasmodium
parasite developed resistance to several antimalarial drugs.
Chloroquine is one of the most successful antimalarials developed that is effective, cheap,
and safe to children and pregnant women. However, due to the emergence of drug
resistance by P. falciparum, its use has been limited. In order to circumvent chloroquine
resistance, reversed chloroquines that reverse the resistance by inhibiting the efflux of
chloroquine were designed in Peyton lab. These hydrid drugs has been found to be potent
against both chloroquine-sensitive and resistant strains of P. falciparum both in vitro and
in vivo.
It’s a challenging task for medicinal chemists to develop new patentable drugs with
strong activity and good pharmacokinetic properties in short time. Click chemistry has
shown to have a cutting-edge advantage in demanding world of medicinal chemistry in
hit finding and lead optimization due to its reliance on extremely quick reactions.
Particularly, the copper(I)-catalyzed cycloaddition reaction between azides and terminal
alkynes to give 1,4-disubstituted-1,2,3-triazoles has become the benchmark of ‘click
chemistry’ by its reliability, selectivity and biocompatibility.
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The incorporation of 1,2,3-Triazoles into pharmacologically active molecules became
more popular after the introduction of copper-catalyzed click chemistry. The stabilty to
acid-base hydrolysis, oxidative-reductive conditions and metabolic degradation make
triazoles not only good passive linkers but also excellent candidates as pharmacophores
and bioisosters. Moreover, these heterocycles readily associate with biological targets via
H-bonding and dipole–dipole interactions.
Series of click compounds were synthesized via copper(I)-catalyzed alkyne-azide
cycloaddition reaction by modifying the aliphatic chains terminal of chloroquine. Three
aliphatic linear chains as linker between the chloroquinoline and the triazole rings were
chosen as optimum length both interms of antimalarial activity and hydrophilicity. The
28 antimalarial click compounds were tested for their in vitro activity against D6, Dd2,
and 7G8 strains of P. falciparum.
The first 18 click compounds was synthesized by reacting the azide analogue with
commercially available terminal alkynes. The first generation click compounds
synthesized contain the triazole ring connected directly to one or two aromatic rings with
different substitutions. Six of the triazole-based click compunds showed better activity
against chloroquine resistant, Dd2 and 7G8, strains of P. falciparum. Particularly, PL403
showed about 4 times better activity than chloroquine with an IC50 values of 12.8 and
14.5 nM against CQ-resistant Dd2 and 7G8 strains respectively.
The second generation triazole antimalarials were synthesized by incorporating
piperazine ring between the triazole and the p-substituted phenyl ring to have a
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protonable nitrogen which increases the basicity of the molecule. The modification has
brought an enhanced antimalarial activity when compared to the first series of
compounds. Six of the nine synthesized piperazinyl-linked triazoles were found to have
potent activity than chloroquine against CQ-resistant strains. The dichloro substituted
triazole, PL448, has proved to possess an excellent activity with IC50 values of 15.2
(Dd2) and 11 (7G8) nM.
In addition to click compounds, other reversed chloroquines were synthesized. A
reversed quinoline hybrid molecule was synthesized by linking 6-quinoline moiety with
benzhydryl-piperazine as a reversal agent. When tested for antimalarial activity, PL370
showed poor antimalarial activity against all strains of P. falciparum. By considering the
effect of an SSRI antidepressant, fluoxetine (Prozac), as a very good chemosentisizer in
reversing both chloroquine and mefloquine resistance, PL410 was synthesized. This hit
was found to be about 20-fold potent than chloroquine with IC50 values of < 2.5 nM for
Dd2 and 7G8 strains of P. falciparum.
In conclusion, the efficiency of synthesizing several triazole-based antimalarials have
proven click chemistry to be fast and efficient reaction. Several of the synthesized
triazole-based antimalarials possessed better activity against chloroquine resistant strains
than chloroquine. Generally, para-substitutions and di-substitutions with short-range and
long-range electron-withdrawing groups were found to be beneficial for having better
antimalarial activity for these group of click compounds.
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CHAPTER 7: Experimental Materials and Methods
7.1. Instrumentation
All starting chemicals were purchased from Sigma-Aldrich Chemical Co. and TCI
America.

Nomenclature

was

done

using

ChemBioDraw

Ultra.

Thin

layer

chromatography was mostly done on Alumina basic column using ethyl-acetate:methanol
(90:10) as mobile phase and visualized by UV lamp (254 nm). The purification was
commonly done by CombiFlash® Rf-200 chromatography using silica column at UV
absorbance of 254 and 280 nM with solid loading, and collecting only the peaks. The
eluents used are chloroform:methanol (90:10) for target compunds and hexane:ethylacetate for intermediate compounds.
The compounds were characterized by NMR and Mass spectroscopy. 1H-,

13

C-, COSY,

HSQC, HMBC and NOESY experiments were run on Bruker 400 MHz instrument, using
the standard pulse sequences provided at 250C. High resolution mass spectrometry was
performed on Bruker micrOTOF-Q instrument. Results were obtained using electospray
ionization (ESI) in the positive mode, at a flow rate of 0.4 mL/min with methanol or
acetonitrile.
7.2. General Synthetic Procedures
PL16 (3-((7-chloroquinolin-4-yl)amino)propan-1-ol)
Purified 4,7-dichloroquinoline (1eq, 5 g, 25.2 mmol) and 3-amino-1-propanol (12.3 eq,
23.7 ml, 309.9 mmol) was healted slowly for 1 hour at 70o C and the temperature was
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increased to 135o C and stirred for 7 additional hours. After the completion was
confirmed by TLC, the reaction mixture was poured to ice-cold H2O (100ml). The white
precipitate formed was filtered by vaccum filtration, washed with water and dried. After
drying, the solid was recrystallized using EtOAC (50ml). The solution was filtered, and
after cooling down, vaccum-filtered and washed with water to give pure, white-yellowish
solid (5.02 g, 84%). 1H NMR (400 MHz, DMSO-d6) δ 8.39 (d, J = 5.5 Hz, 1H), 8.25 (d, J
= 9.0 Hz, 1H), 7.78 (d, J = 2.2 Hz, 1H), 7.44 (dd, J = 9.0, 2.3 Hz, 1H), 7.30 (t, J = 5.4 Hz,
1H), 6.48 (d, J = 5.4 Hz, 1H), 3.55 (t, J = 6.2 Hz, 2H), 3.39 – 3.28 (m, 7H), 1.88 – 1.76
(m, 2H).
PL28 (2-((7-chloroquinolin-4-yl)amino)ethan-1-ol)
A mixture of purified 4,7-dichloroquinoline (1 eq, 5 g, 25.25 mmol) and ethanolamine
(10 eq, 15.24 ml, 252.5 mmol) was heated with stirring overnight at 130 oC. After the
reaction mixture was cooled to RT, it was poured to pre-cooled water (150 ml). The
white precipitate formed was filtered and dried. After drying, the solid was recrystallized
by methanol (100 ml), cooled in ice and filtered by vaccum-filtration to give a pure white
solid (4.48 g, 80 %). 1H NMR (600 MHz, DMSO-d6) δ 8.39 (d, J = 5.4 Hz, 1H), 8.27 (d,
J = 9.0 Hz, 1H), 7.79 (d, J = 2.3 Hz, 1H), 7.45 (dd, J = 9.0, 2.4 Hz, 1H), 7.27 (t, J = 5.6
Hz, 1H), 6.50 (d, J = 5.5 Hz, 1H), 3.67 (t, J = 6.1 Hz, 2H), 3.36 (q, J = 5.8 Hz, 2H).
PL29 (3-((7-chloroquinolin-4-yl)amino)propyl methanesulfonate)
To a suspension of PL16 (1 eq, 5 g, 21.2 mmol) in anhydrous THF (100ml) stirring under
N2 and cooled in an ice-bath, triethylamine (2 eq, 5.9 ml, 42.3 mmol) was added. After
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the mixture was cooled to 0 oC, methane-sulfonyl chloride (1.3 eq, 2.13 ml, 27.6 mmol)
was added very slowly keeping the temperature below 10 oC and the reaction was stirred
for 1 hour. After the completion was confirmed by TLC, work-up was done by liquidliquid extraction by adding saturated NaHCO3 (100ml). After separating the organic
layer, the aqueous layer was extracted with diethyl-ether (200ml and then 2*100ml). The
orgainic layers were mixed and dried by anhydrous MgSO4, concentrated by rotovap and
dried to give white-yellowish solid (5.4 g, 82%). 1H NMR (400 MHz, DMSO-d6) δ 8.43
(d, J = 5.3 Hz, 1H), 8.28 (d, J = 9.0 Hz, 1H), 7.82 (d, J = 2.2 Hz, 1H), 7.48 (dd, J = 9.0,
2.3 Hz, 1H), 7.36 (t, J = 5.5 Hz, 1H), 6.52 (d, J = 5.4 Hz, 1H), 4.37 (t, J = 6.2 Hz, 2H),
3.51 – 3.33 (m, 2H), 3.21 (s, 3H), 2.10 (p, J = 6.5 Hz, 2H).
PL30 (2-((7-chloroquinolin-4-yl)amino)ethyl methanesulfonate)
PL28 (1 eq, 5 g, 22.5 mmol) was dissolved in dry acetone (100 ml) and triethylamine (1.5
eq, 4.7 ml, 33.7 mmol) was added. The mixture was chilled to 0 oC in an ice-bath and the
reaction was carried under N2. Methane-sulfonylchloride (1.2 eq, 2.1 ml, 27 mmol) was
added drop-wise keeping the temperature below 10 oC. The reaction was continued to run
with stirring for 5 hours. After the completion, the solid was filtered and the solvent was
evaporated. The two solids were combined and washed by saturated NaHCO3 (100ml).
The orgainic layer was dried by anhydrous MgSO4, filtered and concentrated to give
white solid (5.8 g, 85%). 1H NMR (400 MHz, DMSO-d6) δ 8.44 (d, J = 5.4 Hz, 1H), 8.26
(d, J = 9.0 Hz, 1H), 7.85 – 7.76 (m, 1H), 7.55 – 7.43 (m, 2H), 6.60 (d, J = 5.5 Hz, 1H),
4.44 (t, J = 5.4 Hz, 2H), 3.68 (q, J = 5.4 Hz, 2H), 3.17 (s, 3H).
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PL49 (7-chloro-4-(piperazin-1-yl)quinoline)
4,7-dichloroquinline (1 eq, 2.5 g, 12.62 mmol) and anhydrous piperazine (7 eq, 7.6 g,
88.36 mmol) were refluxed in ethanol (37.5 ml) for 12 hours. After completion, the
solvent was evaporated and the solid was dissolved in dichloromethane (50 ml). The
solution was washed with saturated NaHCO3 (4 * 25 ml). Finally the organic layer was
separated, dried by anhydrous MgSO4, filtered and concentrated. The compound was pure
enough to be used in the next step without purification (2.62 g, 84 %). 1H NMR (400
MHz, CDCl3) δ 8.72 (d, J = 5.0 Hz, 1H), 8.03 (d, J = 2.1 Hz, 1H), 7.95 (d, J = 8.9 Hz,
1H), 7.42 (dd, J = 9.0, 2.1 Hz, 1H), 6.83 (d, J = 5.0 Hz, 1H), 3.23 – 3.12 (m, 9H), 1.79 (s,
1H, NH).
PL107 (N1-(7-chloroquinolin-4-yl)propane-1,3-diamine)
4,7-dichloroquinoline (1 eq, 2.3 g, 11.61 mmols) and 1,3-diaminopropane (4.4 eq, 4.27
ml, 51.1 mmols) were stirred neatly for 1.5 hours at 80 oC and 6 hours at 145 oC. After
the completion of the reaction was confirmed by TLC, it was cooled to room temperature.
NaOH (10%, 7.2 ml) was added and the mixture was stirred on a sonicator. The
precipitate was filtered by vaccum-filtration and washed with excess water and dried to
give white solid (2.5 g, 91 %). 1H NMR (400 MHz, DMSO-d6) δ 8.38 (t, J = 5.3 Hz, 1H),
8.27 (dd, J = 21.6, 9.1 Hz, 1H), 7.78 (d, J = 2.3 Hz, 1H), 7.44 (ddd, J = 8.8, 6.1, 2.3 Hz,
1H), 6.49 (dd, J = 16.2, 5.4 Hz, 1H), 3.43 (q, J = 6.4 Hz, 1H), 3.33 (t, J = 6.9 Hz, 2H),
3.07 (s, 2H), 2.70 (t, J = 6.5 Hz, 2H), 1.75 (p, J = 6.7 Hz, 2H).
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PL190 (N-(piperidin-4-yl)-1,1-di(pyridin-2-yl)methanimine)
2, 2’-dipyridyl-ketone (1 eq, 3.0 g, 16.3 mmol) was dissolved in toluene (70 ml). 4aminopiperidine (1.15 eq, 1.98 ml, 18.7 mmol) was added, followed by ptoluenesulfonic-acid (0.1 g). The reaction was refluxed while stirring and using deanstark apparatus to continuously remove the water by-product. After the completion of the
reaction, the solvent was evaporated and purified by combi-flash chromatography on
silica column (1.27 g, 29 %). 1H NMR (400 MHz, Chloroform-d) δ 8.72 (dt, J = 5.0, 1.3
Hz, 1H), 8.55 – 8.46 (m, 1H), 8.15 (dt, J = 8.0, 1.2 Hz, 1H), 7.77 (dtd, J = 26.2, 7.8, 1.8
Hz, 2H), 7.38 – 7.09 (m, 3H), 3.39 (tt, J = 9.4, 4.5 Hz, 1H), 3.18 – 3.02 (m, 2H), 2.79 –
2.48 (m, 2H), 1.87 – 1.65 (m, 4H).
PL294 (7-chloro-N-(piperidin-4-yl)quinolin-4-amine)
4,7-dichloroquinoline (1 eq, 5 g, 25 mmol) and 4-aminopiperidine (5 eq, 13.4 ml, 126
mmol) in N,N-diisopropylethylamine (100 ml) was heated at 100 oC for 20 hours. The
DIPEA was evaporated and the crude was purified by combi-flash chromatography in
silica column and using DCM:MeOH:Et3N (8.9:1:0.1) as eluents to give a pure solid
(3.10 g, 47 %). 1H NMR (400 MHz, CDCl3): δ 8.62 (d, J = 5.2, 1H), 7.96 (d, J = 2.0,
1H), 7.85 (d, J = 8.9, 1H), 7.35 (dd, J = 8.9, 2.0, 1H), 6.75 (d, J = 5.2, 1H), 5.24 (s, 1H),
3.48 (d, J = 12.0, 2H), 2.89 (m, 1H), 2.82 (t, J = 11.6, 2H), 1.97 (d, J = 12.0, 2H), 1.61
(m, 4H).
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PL323 (3-chloro-N-(quinolin-6-yl)propanamide)
6-aminoquinoline (1 eq, 5.0 g, 34.68 mmol) and triethylamine (1.2 eq, 5.8 ml, 41.62
mmols) were mixed in anhydrous dichloromethane (40 ml) on ice-bath. 3Chloropropionyl-chloride (1.05 eq, 3.47 ml, 36.41 mmols) was added dropwise keeping
the temperature below 10 oC. The reaction was stirred for 1 hour. Saturated NaHCO3 (25
ml) was added and the aqueous layer was extracted by dichloromethane (3 * 10ml). The
organic layer was dried by anhydrous MgSO4, filtered and dried. The crude was purified
by combi-flash chromatography using silica column and EtOAC:MeOH as eluents to
give a yellow solid (2.49 g, 50 %). 1H NMR (400 MHz, Chloroform-d) δ 1H NMR (400
MHz, DMSO-d6) δ 10.66 (s, 1H), 8.81 (dd, J = 4.2, 1.7 Hz, 1H), 8.41 – 8.29 (m, 2H),
8.00 (d, J = 9.0 Hz, 1H), 7.81 (dd, J = 9.1, 2.4 Hz, 1H), 7.50 (dd, J = 8.3, 4.2 Hz, 1H),
3.93 (t, J = 6.3 Hz, 2H), 2.90 (t, J = 6.3 Hz, 2H).
PL326 (N-(3-chloropropyl)quinolin-6-amine)
PL323 (1 eq, 1.87 g, 7.97 mmol) was dissolved in tetrahydrofuran (20ml). LiAlH4 in 1M
THF (3eq, 23.9ml, 23.9 mmol) was slowly added under N2 in an ice-bath. An additional
30ml of THF was added and the reaction was allowed to stir overnight . After completion
was confirmed by TLC, the reaction mixture was quenched with EtOAc (20ml) and
MeOH (20ml), and then by citric acid solution. After filtering the yellow precipitate, the
solution was extracted using diethyl-ether (2 * 20ml). The organic layer was separated,
dried by anhydrous MgSO4, filtered and concentrated to get a brownish-oily compound
(1.01g, 57.4%). 1H NMR (400 MHz, Chloroform-d) δ 8.61 – 8.53 (m, 1H), 7.94 – 7.87
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(m, 1H), 7.84 (d, J = 9.1 Hz, 1H), 7.23 (dt, J = 8.3, 4.2 Hz, 1H), 7.06 (dd, J = 9.1, 2.6 Hz,
1H), 6.66 (dd, J = 8.0, 2.6 Hz, 1H), 3.17 (t, J = 7.2 Hz, 2H), 1.72 – 1.66 (m, 2H), 1.04 (t,
J = 7.4 Hz, 2H).
PL334 (2-chloro-N-(quinolin-6-yl)acetamide)
6-aminoquinoline (1 eq, 1.0 g, 6.94 mmol) and triethylamine (1.2 eq, 1.16 ml, 14.15
mmols) were mixed in anhydrous dichloromethane (40 ml) on ice-bath. Chloroacetylchloride (1.05 eq, 0.58 ml, 7.29 mmols) was added dropwise keeping the
temperature below 10oC. The reaction was stirred for 1 hour. Saturated NaHCO3 (25 ml)
was added and the aqueous layer was extracted by DCM (3 * 10ml). The organic layer
was dried by anhydrous MgSO4, filtered and dried. The crude was purified by combiflash chromatography using silica column and EtOAC:MeOH as eluents to give a pure
solid (1.10 g, 66 %). 1H NMR (400 MHz, Chloroform-d) δ 8.87 (dd, J = 4.2, 1.7 Hz, 1H),
8.53 (s, 1H), 8.35 (d, J = 2.4 Hz, 1H), 8.18 – 8.13 (m, 1H), 8.10 (d, J = 9.0 Hz, 1H), 7.65
(dd, J = 9.0, 2.5 Hz, 1H), 7.42 (dd, J = 8.3, 4.2 Hz, 1H), 4.26 (s, 2H).
PL369 (3-(4-benzhydrylpiperazin-1-yl)-N-(quinolin-6-yl)propanamide)
PL323 (1eq, 2.0g, 8.53 mmol) was dissolved in acetonitrile (40 ml). 1benzhydrylpiperazine (1.05 eq, 2.26 g, 8.96 mmol), anhydrous K2CO3 (2.4 eq, 2.97 g,
21.50 mmol) and KI (1 eq, 1.42 g, 8.53 mmol) were all added to the solution. The
reaction was refluxed with stirring for 3 days. After completion was confirmed, the
acetonitrile solvent was evaporated and the slurry was taken up by EtOAC (20 ml) and
water (40 ml). The aqueous phase was extracted by EtOAC (2 * 10 ml) and the organic
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layer was washed with saturated NaHCO3 (15 ml), and then washed with brine (20 ml).
The organic layer was dried by anhydrous MgSO4, filtered and concentrated. The crude
was purified by combi-flash chromatography using silica column and and EtOAC:MeOH
(85:15) as eluents to give a yellowish solid (1.6 g, 80 %). 1H NMR (400 MHz,
Chloroform-d) δ 11.41 (s, 1H), 8.81 (dd, J = 4.3, 1.7 Hz, 1H), 8.44 (d, J = 2.3 Hz, 1H),
8.14 – 8.09 (m, 1H), 8.02 (d, J = 9.0 Hz, 1H), 7.48 – 7.43 (m, 4H), 7.41 – 7.34 (m, 2H),
7.31 (dd, J = 8.3, 6.8 Hz, 4H), 7.25 – 7.19 (m, 2H), 4.38 (s, 1H), 2.50–2.81 (ddd, J = 80.7,
7.0, 5.2 Hz, 8H).

13

C NMR (101 MHz, Chloroform-d) δ 171.0, 149.1, 145.3, 142.1,

136.6, 135.9, 130.1, 128.6, 128.0, 127.2, 123.1, 121.5, 115.6, 75.9, 53.6, 52.6, 52.0, 32.5.
m/z 450.25 M + H (calculated 450.59).
PL370 (N-(3-(4-benzhydrylpiperazin-1-yl)propyl)quinolin-6-amine)
PL369 (1 eq, 1.6 g, 3.66 mmol) was dissolved in tetrahydrofuran (20 ml). Under N2,
LiAlH4 in 2.5M THF (5 eq, 7.33 ml, 18.31 mmol) was added into the reaction mixture.
The reaction was allowed to run at 0 oC overnight. After completion, the solution was
quenched by citric acid solution. To the yellow-greenish suspension formed, NaOH (2.75
M, 1 ml) and saturated NaHCO3 (20 ml) was added, and the aqueous phase was extracted
with diethylether (2 * 15 ml). The organic phase was washed with water (10 ml) and
salted out with brine (10 ml). Finally, the organic layer was dried by anhydrous MgSO 4,
filtered and evaporated to give a brownish, oily solid. The crude (0.76 g) was purified by
combi-flash chromatography by dissolving in acetone and small amount of methanol.
Silica gel sorbent (7.6 g) was added and the suspension was stirred on sonicator before
evaporating the solvent. The solid was purified in silica column (40 g) using
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EtOAC:MeOH (85:15) as eluents by collecting only the peaks for 20 minutes twice (0.42
g, 56 %). 1H NMR (400 MHz, Chloroform-d) δ 8.58 (dd, J = 4.3, 1.7 Hz, 1H), 7.91 –
7.81 (m, 2H), 7.47 – 7.39 (m, 4H), 7.32 – 7.15 (m, 8H), 7.02 (dd, J = 9.1, 2.6 Hz, 1H),
6.62 (d, J = 2.6 Hz, 1H), 4.28 (s, 1H), 3.26 (t, J = 6.2 Hz, 2H), 2.61 – 2.34 (m, 10H), 1.84
(p, J = 6.3 Hz, 2H).
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C NMR (101 MHz, Chloroform-d) δ 149.1, 145.3, 142.1, 136.6,

135.9, 130.1, 128.6, 128.0, 127.2, 123.1, 121.5, 115.6, 75.9, 53.6, 52.6, 52.0, 41.1, 32.5.
m/z 436.27 M + H (calculated 436.60).
PL403 (7-chloro-N-(3-(4-(4-(trifluoromethoxy)phenyl)-1H-1,2,3-triazol-1yl)propyl)quinolin-4-amine)
To

a

stirred

solution

of

PL409

(1

eq,

0.16

g,

0.61

mmol),

4-

(trifluoromethoxy)phenylacetylene (1.07 eq, 0.1 ml, 0.65 mmol) in tert-butanol (7 ml),
was added a solution of CuSO4. 5H2O (0.2 eq, 0.030 g, 0.12 mmol) and sodium ascorbate
(0.4 eq, 0.048 g, 0.24 mmol) in water (7 ml), and the mixture was stirred for 4 hours at 40
o

C. After completion, CHCl3 (20 ml) was added and the mixture was washed with water

(2 * 100 ml). Finally the organic layer was dried by anhydrous MgSO4, filtered and
concentrated to give a white solid (0.08 g, 30 %). 1H NMR (400 MHz, DMSO-d6) δ 8.68
(s, 1H), 8.41 (s, 1H), 8.26 (d, J = 9.0 Hz, 1H), 7.99 – 7.90 (m, 2H), 7.79 (s, 1H), 7.50 –
7.41 (m, 3H), 7.36 (t, J = 5.4 Hz, 1H), 6.49 (d, J = 4.9 Hz, 1H), 4.58 (t, J = 6.9 Hz, 2H),
3.37 (d, J = 6.5 Hz, 2H), 2.30 (p, J = 6.9 Hz, 2H), 13C NMR (101 MHz, DMSO-d6) δ
145.0, 133.4, 130.2 ,126.9 , 124.1, 122.0, 121.6, 47.7, 40.1, 28.3. m/z 447.11 M + H
(calculated 447.85).
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PL404 ((1-(3-((7-chloroquinolin-4-yl)amino)propyl)-1H-1,2,3-triazol-4yl)diphenylmethanol)
To a stirred solution of PL409 (1 eq, 0.50 g, 1.9 mmol), 1,1-diphenyl-2-propyn-1-ol (1.07
eq, 0.42 g, 2.84 mmol) in tert-butanol (23 ml), a solution of CuSO4. 5H2O (0.2 eq, 0.095
g, 0.38 mmol) and sodium ascorbate (0.4 eq, 0.15 g, 0.76 mmol) in water (23 ml) was
added, and the mixture was stirred for 3 hours at 40 oC. After completion, the reaction
mixture was cooled to RT and taken by CHCl3 (60 ml) and washed with water (3 * 300
ml). Finally the organic layer was dried by anhydrous MgSO4, filtered and concentrated
The crude was purified using combi-flash chromatography in silica column by eluting
using CHCl3:MeOH (90:10) to give a pure white-yellowish solid (0.35 g, 41 %). 1H
NMR (400 MHz, DMSO-d6) δ 8.37 (d, J = 5.4 Hz, 1H), 8.26 (d, J = 9.0 Hz, 1H), 7.88 (s,
1H), 7.79 (d, J = 2.3 Hz, 1H), 7.46 (dd, J = 9.0, 2.3 Hz, 1H), 7.40 – 7.17 (m, 10H), 6.54
(s, 1H), 6.40 (d, J = 5.4 Hz, 1H), 4.51 (t, J = 6.9 Hz, 2H), 3.33 – 3.24 (m, 2H), 2.22 (p, J
= 7.0 Hz, 2H). 13C NMR (101 MHz, DMSO-d6) δ 153.9 , 151.9 , 149.9 , 149.0 , 147.1 ,
133.4 , 127.5 (d, J = 3.6 Hz), 127.0 , 126.6 , 124.1 (d, J = 3.8 Hz), 123.4 , 117.5 , 98.6 ,
75.7 , 59.7 , 47.2 , 38.9 , 28.5 , 14.1. m/z 469.17 M + H (calculated 469.97).
PL405 (7-chloro-N-(3-(4-(2-methoxyphenyl)-1H-1,2,3-triazol-1-yl)propyl)quinolin-4amine)
To a stirred solution of PL409 (1 eq, 0.50 g, 1.9 mmol), 2-ethynylanisole (1.07 eq, 0.26
ml, 2.04 mmol) in tert-butanol (19 ml), was added CuSO4. 5H2O (0.2 eq, 0.095 g, 0.38
mmol) and sodium ascorbate (0.4 eq, 0.15 g, 0.76 mmol) in water (19 ml), and the
mixture was stirred for 3 hours at 40 oC. After completion, the crude mixture was taken
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by CHCl3 (25 ml) and washed with water (3 * 120 ml). Finally the organic layer was
dried by anhydrous MgSO4, filtered and concentrated. The crude was purified using
combi-flash chromatography in silica column by eluting using CHCl3:MeOH (90:10) to
give a pure solid (0.54 g, 72 %). 1H NMR (400 MHz, DMSO-d6) δ 8.42 (s, 1H), 8.34 –
8.26 (m, 1H), 8.13 (dd, J = 7.7, 1.8 Hz, 1H), 7.81 (s, 1H), 7.45 (dd, J = 13.8, 7.3 Hz, 2H),
7.33 (td, J = 8.0, 1.8 Hz, 1H), 7.16 – 6.99 (m, 3H), 6.51 (s, 1H), 4.58 (t, J = 6.9 Hz, 2H),
3.89 (s, 3H), 3.34 (q, J = 6.4 Hz, 2H), 2.29 (p, J = 6.7 Hz, 2H).

13

C NMR (101 MHz,

DMSO-d6) δ 155.3 , 141.7 , 133.5 , 128.8 , 126.5 , 124.2 , 124.0 , 120.6 , 119.1 , 111.5 ,
55.4 , 47.4 , 40.1 , 28.5. m/z 393.14 M + H (calculated 393.88).
PL406 (7-chloro-N-(3-(4-(3-methoxyphenyl)-1H-1,2,3-triazol-1-yl)propyl)quinolin-4amine)
To a stirred solution of PL409 (1 eq, 0.50 g, 1.9 mmol), 3-ethynylanisole (1.07 eq, 0.26
ml, 2.04 mmol) in tert-butanol (19 ml), was added CuSO4. 5H2O (0.2 eq, 0.095 g, 0.38
mmol) and sodium ascorbate (0.4 eq, 0.15 g, 0.76 mmol) in water (19 ml) was added and
the mixture was stirred for 3 hours at 40 oC. After completion, the crude mixture was
taken by CHCl3 (25 ml) and washed with water (3 * 120 ml). Finally the organic layer
was dried by anhydrous MgSO4, filtered and concentrated. The crude was purified using
combi-flash chromatography in silica column by eluting using CHCl3:MeOH (90:10) to
give a pure white-yellowish solid (0.38 g, 51 %). 1H NMR (400 MHz, DMSO-d6) δ 8.64
(s, 1H), 8.29 (d, J = 8.9 Hz, 1H), 7.81 (s, 1H), 7.54 – 7.31 (m, 5H), 6.90 (ddd, J = 8.1,
2.6, 1.2 Hz, 1H), 6.53 (s, 1H), 4.56 (t, J = 6.9 Hz, 2H), 3.81 (s, 3H), 3.36 (q, J = 6.5 Hz,
2H), 2.30 (p, J = 7.0 Hz, 2H). 13C NMR (101 MHz, DMSO-d6) δ 159.6 , 150.2 , 146.2 ,
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133.7 , 132.1 , 130.0 , 124.2, 121.7 , 117.4 , 113.5 , 110.3 , 55.1 , 47.6 , 38.9 , 28.3. m/z
393.14 M + H (calculated 393.88).
PL407 (7-chloro-N-(3-(4-(2-fluorophenyl)-1H-1,2,3-triazol-1-yl)propyl)quinolin-4amine)
To a stirred solution of PL409 (1 eq, 0.50 g, 1.9 mmol), 2-fluorophenylacetlene (1.07 eq,
0.24 ml, 2.04 mmol) in tert-butanol (15 ml), was added CuSO4. 5H2O (0.2 eq, 0.095 g,
0.38 mmol) and sodium ascorbate (0.4 eq, 0.15 g, 0.76 mmol) in water (15 ml) was added
and the mixture was stirred for 3 hours at 40 oC. After completion, the mixture of
solvents was evaporated and the solid was purified using combi-flash chromatography in
silica column by eluting using CHCl3:MeOH (90:10) to give a pure white-yellowish solid
(0.10 g, 26 %). 1H NMR (400 MHz, DMSO-d6) δ 8.50 (d, J = 3.7 Hz, 1H), 8.41 (d, J =
5.3 Hz, 1H), 8.26 (dd, J = 9.0, 5.6 Hz, 1H), 8.13 (td, J = 7.6, 1.7 Hz, 1H), 7.79 (d, J = 2.4
Hz, 1H), 7.45 (dd, 1H), 7.40 (dt, 1H), 7.34(t, 3H), 6.48 (dd, J = 11.0, 5.4 Hz, 1H), 4.62 (t,
J = 6.7 Hz, 2H), 3.32 (s, 2H), 2.30 (p, J = 6.8 Hz, 2H).13C NMR (101 MHz, DMSO-d6) δ
151.9, 149.9, 149.0 , 133.4 , 127.4, 124.9 , 124.1 , 117.5 , 98.7 , 48.5 , 47.6 , 40.1 , 28.4 ,
27.1. m/z 381.12 M + H (calculated 381.84).
PL408 (7-chloro-N-(3-(4-(3,4-difluorophenyl)-1H-1,2,3-triazol-1-yl)propyl)quinolin4-amine)
To a stirred solution of PL409 (1 eq, 0.50 g, 1.9 mmol), 3,4-difluorophenylacetlene (1.07
eq, 0.25 ml, 2.04 mmol) in tert-butanol (15 ml), CuSO4. 5H2O (0.2 eq, 0.095 g, 0.38
mmol) and sodium ascorbate (0.4 eq, 0.15 g, 0.76 mmol) in water (15 ml) was added and
the mixture was stirred for 3 hours at 40 oC. After completion, the mixture of solvents
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was evaporated and the solid was purified using combi-flash chromatography in silica
column by eluting using CHCl3:MeOH (90:10) to give a pure white-yellowish solid (0.58
g, 76 %). 1H NMR (400 MHz, DMSO-d6) δ 8.66 (s, 1H), 8.40 (d, 1H), 8.24 (d, 1H), 7.84
(dt, 1H), 7,78 (d, 1H), 7.67 (dtd, J = 10.6, 4.6, 3.6, 1.9 Hz, 1H), 7.60 – 7.29 (m, 3H), 6.49
(d, 1H), 4.56 (t, 2H), 3.36 (dd, J = 14.3, 7.7 Hz, 2H), 2.29 (p, J = 7.2 Hz, 2H). 13C NMR
(101 MHz, DMSO-d6) δ 151.9 , 149.9, 148.9, 133.4, 127.5 , 124.1, 122.1 , 118.2 , 98.8 ,
47.7 , 40.1 , 28.2. m/z 399.11 M + H (calculated 399.83).
PL409 (N-(3-azidopropyl)-7-chloroquinolin-4-amine)
PL29 (1 eq, 7.0 g, 22.2 mmol) was dissolved in anhydrous dimethylformamide (100ml).
Sodium azide (2 eq, 2.9 g, 44.5 mmol) was added and the mixture was stirred at 55 oC for
12 hours. After completion, De-ionized water (135 ml) was added and the aqueous layer
was extracted with toluene (3*330ml). The organic layer was dried with brine (130ml),
dried by anhydrous MgSO4, filtered and evaporated to give yellow solid (5.1 g, 88 %). 1H
NMR (400 MHz, Chloroform-d) δ 8.55 (d, J = 5.3 Hz, 1H), 7.96 (d, J = 2.1 Hz, 1H), 7.67
(d, J = 8.9 Hz, 1H), 7.36 (dd, J = 9.0, 2.2 Hz, 1H), 6.42 (d, J = 5.3 Hz, 1H), 5.35 (t, J =
5.4 Hz, 1H), 3.57 – 3.40 (m, 4H), 2.02 (p, J = 6.6 Hz, 2H).
PL410 (N1-(7-chloroquinolin-4-yl)-N3-methyl-N3-(3-phenyl-3-(4(trifluoromethyl)phenoxy)propyl)propane-1,3-diamine)
First, the free base fluoxetine was prepared by dissolving fluoxetine HCl (1 eq, 0.55 g,
1.59 mmol) in water (7ml). Solid NaHCO3 (2.28 eq, 0.30 g, 3.62 mmol) was added and
the mixture was extracted with dichloromethane (9ml * 3). The organic phase was dried
with anhydrous MgSO4, filtered and evaporated to give yellow oliy liquid (0.51g, 93%).
83

The free-base fluoxetine (1 eq, 0.51 g, 1.65 mmol) was dissolved in tetrahydrofuran
(18ml), followed by addition of PL29 (1.33 eq, 0.69 g, 2.19 mmol) and triethylamine (2.9
eq, 0.67 ml, 4.79 mmol) and the reaction mixture was stirred for 72 hours at 55 oC. After
the reaction completion was confirmed by TLC on alumina plate, the reaction was cooled
to RT and THF was evaporated by rotovap. The crude was washed with EtOAC (25ml)
and saturated NaHCO3 (25ml). The organic layer was separated and the aqueous layer
was washed with EtOAC (2*15ml). The organic layer was finally dried by anhydrous
MgSO4, filtered and evaporated. The crude was purified by combi-flash chromatography
on alumina column using EtOAC:Hexane as eluents to get a yellow solid (0.6g, 69%). 1H
NMR (400 MHz, DMSO-d6) δ 8.37 (d, J = 5.4 Hz, 1H), 8.21 (d, J = 9.0 Hz, 1H), 7.78 (d,
J = 2.2 Hz, 1H), 7.56 – 7.38 (m, 3H), 7.37 – 7.19 (m, 6H), 6.98 (d, J = 8.6 Hz, 2H), 6.40
(d, J = 5.5 Hz, 1H), 5.44 (dd, J = 8.2, 4.8 Hz, 1H), 3.49 – 3.37 (m, 2H), 3.23 (dtd, J =
19.6, 12.8, 6.4 Hz, 2H), 2.57 – 2.26 (m, 2H), 2.19 (s, 3H), 2.16 – 1.86 (m, 2H), 1.86 –
1.70 (m, 2H).

13

C NMR (101 MHz, DMSO-d6) δ 160.5, 151.9, 150.1, 149.0, 141.0,

133.3, 128.5, 127.6, 126.9 – 126.6 (m), 125.9 , 124.0 (d, J = 4.8 Hz), 120.8 , 117.4 ,
116.0 , 98.6 , 77.4 , 54.8 , 53.2 , 41.9 , 40.7 , 35.7 , 25.3 , 22.3. m/z 527.20 M + H
(calculated 528.02).
PL411 (7-chloro-N-(3-(4-phenyl-1H-1,2,3-triazol-1-yl)propyl)quinolin-4-amine)
To a stirred solution of PL409 (1 eq, 0.50 g, 1.9 mmol), Ethynyl-benzene (1eq, 0.21ml,
1.9mmol) in tert-butanol (5ml), CuSO4. 5H2O (0.2eq, 0.095g, 0.38mmol) and sodium
ascorbate (0.4 eq, 0.15 g, 0.76 mmol) in water (5ml) was added and the mixture was
stirred for 4 hours at 40 oC. After completion, the mixture of solvents was evaporated and
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the solid was purified using combi-flash chromatography in silica column by eluting
using CHCl3:MeOH (90:10) to give a pure white-yellowish solid (0.34g, 50%). 1H NMR
(400 MHz, DMSO-d6) δ 8.62 (s, 1H), 8.40 (d, J = 5.4 Hz, 1H), 8.27 (d, 1H), 7.94 – 7.74
(m, 3H), 7.50 – 7.28 (m, 5H), 6.48 (dd, J = 5.5, 3.7 Hz, 1H), 4.59 (dt, J = 11.1, 6.9 Hz,
2H), 3.34 (dt, J = 13.4, 6.9 Hz, 2H), 2.30 (q, 2H).

13

C NMR (101 MHz, DMSO-d6) δ

151.9, 149.9 (d, J = 5.9 Hz), 149.5, 148.9, 146.3, 137.1, 133.4, 130.8, 128.9, 127.8,
127.5, 125.1, 124.1 (d, J = 3.6 Hz), 122.9, 121.5, 119.3, 117.5, 98.7, 47.6, 40.1, 28.34.
m/z 363.13 M + H (calculated 363.85).
PL412 (7-chloro-N-(3-(4-(pyridin-2-yl)-1H-1,2,3-triazol-1-yl)propyl)quinolin-4amine)
To a stirred solution of PL409 (1 eq, 0.25 g, 1.9 mmol), 2-Ethynylpyridine (1eq, 0.1ml,
1.9 mmol) in tert-butanol (5ml), CuSO4. 5H2O (0.2eq, 0.095g, 0.38mmol) and sodium
ascorbate (0.4 eq, 0.15 g, 0.76 mmol) in water (5ml) was added and the mixture was
stirred for 4 hours at 40 oC. After completion, the mixture of solvents was evaporated and
the solid was purified using combi-flash chromatography in silica column by eluting
using CHCl3:MeOH (90:10) to give a yellow solid (0.16g, 46%). 1H NMR (400 MHz,
DMSO-d6) δ 8.48 (s, 2H), 7.45 (s, 1H), 7.37 (s, 1H), 6.76 (s, 1H), 4.70 (s, 2H), 3.17 (d, J
= 5.0 Hz, 2H), 2.09 (s, 2H).
PL413 (7-chloro-N-(3-(4-(p-tolyl)-1H-1,2,3-triazol-1-yl)propyl)quinolin-4-amine)
To a stirred solution of PL409 (1 eq, 0.50 g, 1.9 mmol), 4-Ethynyltoluene (1 eq, 0.24 ml,
1.9 mmol) in tert-butanol (5ml), CuSO4. 5H2O (0.2eq, 0.095g, 0.38mmol) and sodium
ascorbate (0.4 eq, 0.15 g, 0.76 mmol) in water (5ml) was added and the mixture was
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stirred for 4 hours at 40 oC. After completion, the mixture of solvents was evaporated and
the solid was recrystallized by CHCl3:MeOH (90:10) to give a pure solid (0.4g, 56%). 1H
NMR (400 MHz, DMSO-d6) δ 8.55 (s, 1H), 8.41 (s, 1H), 8.29 (d, 1H), 7.81 (d, 1H), 7.71
(d, 2H), 7.46 (d, 1H), 7.43 (t, 1H), 7.25 (d, 2H), 6.52 (d, 1H), 4.55 (t, 2H), 3.43 (d, 2H),
2.32 (s, 3H), 2.27 (q, 2H). 13C NMR (101 MHz, DMSO-d6) δ 137.1, 129.4, 128.0, 125.0,
121.1, 47.5, 28.1, 20.8. m/z 377.14 M + H (calculated 377.88).
PL414 (N-(3-(4-benzyl-1H-1,2,3-triazol-1-yl)propyl)-7-chloroquinolin-4-amine)
To a stirred solution of PL409 (1 eq, 0.50 g, 1.9 mmol), 3-phenyl-1-propyne (1 eq, 0.24
ml, 1.9 mmol) in tert-butanol (5ml), CuSO4. 5H2O (0.2eq, 0.095g, 0.38mmol) and
sodium ascorbate (0.4 eq, 0.15 g, 0.76 mmol) in water (5ml) was added and the mixture
was stirred for 4 hours at 40 oC. After completion, the mixture of solvents was evaporated
and the solid was recrystallized by CHCl3:MeOH (90:10) to give a pure solid (0.33 g,
45%). 1H NMR (400 MHz, DMSO-d6) δ 8.31 (d, J = 6.1 Hz, 1H), 7.88 (s, 1H), 7.82 (d,
1H), 7.46 (dd, J = 10.5, 7.1 Hz, 2H), 7.35 – 7.15 (m, 6H), 6.48 (s, 1H), 4.46 (t, J = 6.9 Hz,
2H), 3.98 (s, 2H), 3.28 (q, J = 6.5 Hz, 2H), 2.20 (p, J = 6.9 Hz, 2H). 13C NMR (101 MHz,
DMSO-d6) δ 150.1, 146.1, 139.6, 133.6, 128.4(d, J = 8.9 Hz), 126.1, 124.3, 122.6, 47.2,
38.9, 31.3, 28.4. m/z 377.14 M + H (calculated 377.88).
PL415 (N-(3-(4-(4-aminophenyl)-1H-1,2,3-triazol-1-yl)propyl)-7-chloroquinolin-4amine)
To a stirred solution of PL409 (1 eq, 0.50 g, 1.9 mmol), 4-ethynylaniline (1 eq, 0.22 g,
1.9 mmol) in tert-butanol (5 ml), CuSO4. 5H2O (0.2 eq, 0.095 g, 0.38 mmol) and sodium
ascorbate (0.4 eq, 0.15 g, 0.76 mmol) in water (5ml) was added and the mixture was
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stirred for 4 hours at 40 oC. After completion, the mixture of solvents was evaporated and
the solid was recrystallized by CHCl3 : MeOH (90:10) to give a pure solid (0.52 g, 72 %).
1

H NMR (400 MHz, DMSO-d6) δ 8.40 (s, 1H), 8.28 (d, J = 20.1 Hz, 2H), 7.80 (d, J = 2.4

Hz, 1H), 7.53 – 7.35 (m, 4H), 6.62 (m, 2H), 6.48 (d, J = 5.4 Hz, 1H), 5.22 (s, 2H), 4.51 (t,
J = 6.9 Hz, 2H), 3.35 (m, 2H), 2.25 (dq, J = 11.5, 5.8, 4.6 Hz, 2H). 13C NMR (101 MHz,
DMSO-d6) δ 151.8, 150.0, 148.5, 147.3, 133.5, 127.3, 126.1, 124.1 (d, J = 8.6 Hz),
119.3, 118.4, 113.9, 98.8, 47.3, 38.8, 28.4. m/z 378.14 M + H (calculated 378.86).
PL416 (N-(3-(4-(4-bromophenyl)-1H-1,2,3-triazol-1-yl)propyl)-7-chloroquinolin-4amine)
To a stirred solution of PL409 (1 eq, 0.25 g, 0.95 mmol), 1-Bromo-4-Ethynylbenzene (1
eq, 0.17 g, 0.95 mmol) in tert-butanol (4 ml), CuSO4. 5H2O (0.2 eq, 0.047 g, 0.19 mmol)
and sodium ascorbate (0.4eq, 0.075 g, 0.38 mmol) in water (4 ml) was added and the
mixture was stirred for 4 hours at 40 oC. After completion, the mixture of solvents was
evaporated and the solid was recrystallized by CHCl3 : MeOH (90:10) to give a pure solid
(0.29 g, 69 %). 1H NMR (400 MHz, DMSO-d6) δ 8.65 (s, 1H), 8.58 (s, 1H), 7.78 (d, J =
8.1 Hz, 2H), 7.68 – 7.55 (m, 3H), 7.45 (d, J = 8.6 Hz, 1H), 4.56 (t, J = 6.8 Hz, 2H), 3.34
(d, J = 5.9 Hz, 2H), 2.35 – 2.19 (m, 2H). 13C NMR (101 MHz, DMSO-d6) δ 145.3, 131.8,
129.9, 127.1, 124.6, 121.9, 120.8, 47.6, 40.1, 38.8, 28.1. m/z 443.04 M + H (calculated
442.75).
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PL417 (7-chloro-N-(3-(4-(4-methoxyphenyl)-1H-1,2,3-triazol-1-yl)propyl)quinolin-4amine)
To a stirred solution of PL409 (1 eq, 0.25 g, 0.95 mmol), 4-Ethynylanisole (1 eq, 0.13
ml, 0.95 mmol) in tert-butanol (4 ml), CuSO4. 5H2O (0.2 eq, 0.047 g, 0.19 mmol) and
sodium ascorbate (0.4eq, 0.075 g, 0.38 mmol) in water (4 ml) was added and the mixture
was stirred for 4 hours at 40 oC. After completion, the mixture of solvents was evaporated
and the solid was recrystallized by CHCl3 : MeOH (90:10) to give a pure solid (0.19 g,
51 %). 1H NMR (400 MHz, DMSO-d6) δ 8.49 (s, 1H), 8.33 (s, 1H), 7.84 (s, 1H), 7.79 –
7.70 (m, 2H), 7.54 – 7.43 (m, 2H), 7.05 – 6.97 (m, 2H), 6.57 (s, 1H), 4.54 (t, J = 6.9 Hz,
2H), 3.79 (d, J = 1.2 Hz, 3H), 3.34 (d, J = 6.4 Hz, 2H), 2.27 (tt, J = 12.9, 5.7 Hz, 2H). 13C
NMR (101 MHz, DMSO-d6) δ 158.9, 146.2, 126.4, 124.3, 120.5, 114.3, 55.1, 47.5, 38.8,
28.3. m/z 393.14 M + H (calculated 393.88).
PL418 (7-chloro-N-(3-(4-(4-chlorophenyl)-1H-1,2,3-triazol-1-yl)propyl)quinolin-4amine)
To a stirred solution of PL409 (1 eq, 0.25 g, 0.95 mmol), 1-Chloro-4-Ethynylbenzene (1
eq, 0.13 g, 0.95 mmol) in tert-butanol (4 ml), CuSO4. 5H2O (0.2 eq, 0.047 g, 0.19 mmol)
and sodium ascorbate (0.4eq, 0.075 g, 0.38 mmol) in water (4 ml) was added and the
mixture was stirred for 4 hours at 40 oC. After completion, the mixture of solvents was
evaporated and the solid was recrystallized by CHCl3 : MeOH (90:10) to give a pure solid
(0.28 g, 76 %). 1H NMR (400 MHz, DMSO-d6) δ 8.64 (s, 1H), 7.84 (d, J = 8.3 Hz, 2H),
7.48 (dd, J = 26.9, 8.3 Hz, 4H), 6.91 (s, 1H), 4.57 (t, J = 6.7 Hz, 2H), 3.34 (p, J = 5.4, 4.4
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Hz, 2H), 2.36 – 2.19 (m, 2H).

13

C NMR (101 MHz, DMSO-d6) δ 145.2, 132.2, 129.6,

128.9, 126.8, 124.5, 121.8, 47.6, 38.8, 28.9, 28.1. m/z 397.09 M + H (calculated 398.29).
PL419 (7-chloro-N-(3-(4-(4-(trifluoromethyl)phenyl)-1H-1,2,3-triazol-1yl)propyl)quinolin-4-amine)
To a stirred solution of PL409 (1 eq, 0.25 g, 0.95 mmol), 1-Ethynyl-4-(trifluoromethyl)
benzene) (1 eq, 0.16 ml, 0.95 mmol) in tert-butanol (4 ml), CuSO4. 5H2O (0.2 eq, 0.047
g, 0.19 mmol) and sodium ascorbate (0.4eq, 0.075 g, 0.38 mmol) in water (4 ml) was
added and the mixture was stirred for 4 hours at 40 oC. After completion, the mixture of
solvents was evaporated and the solid was recrystallized by CHCl3 : MeOH (90:10) to
give a pure solid (0.28 g, 68 %). 1H NMR (400 MHz, DMSO-d6) δ 8.77 (s, 1H), 8.34 (s,
1H), 8.04 (d, J = 8.0 Hz, 2H), 7.81 (d, J = 8.0 Hz, 2H), 7.58 (t, J = 5.3 Hz, 1H), 7.46 (d, J
= 8.8 Hz, 1H), 6.63 (s, 1H), 4.60 (t, J = 6.7 Hz, 2H), 3.39 (q, J = 6.0 Hz, 2H), 2.32 (p, J =
6.9 Hz, 2H). 13C NMR (101 MHz, DMSO-d6) δ 144.9, 134.7, 133.8, 127.8, 125.9 – 125.7
(m), 125.6, 124.4, 122.8 (d, J = 9.9 Hz), 47.7, 38.8, 28.1. m/z 431.12 M + H (calculated
431.85).
PL420 (7-chloro-N-(3-(4-(4-fluorophenyl)-1H-1,2,3-triazol-1-yl)propyl)quinolin-4amine)
To a stirred solution of PL409 (1 eq, 0.50 g, 1.9 mmol), 1-Ethynyl-4-Fluorobenzene (1
eq, 0.23 g, 1.9 mmol) in tert-butanol (5 ml), CuSO4. 5H2O (0.2 eq, 0.095 g, 0.38 mmol)
and sodium ascorbate (0.4eq, 0.15 g, 0.76 mmol) in water (5 ml) was added and the
mixture was stirred for 4 hours at 50 oC. After completion, the mixture of solvents was
evaporated and the solid was recrystallized by CHCl3 : MeOH (90:10) to give a pure solid
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(0.61 g, 84 %). 1H NMR (400 MHz, DMSO-d6) δ 8.60 (s, 1H), 8.45 (s, 1H), 7.92 – 7.81
(m, 2H), 7.45 (d, J = 8.4 Hz, 2H), 7.29 (t, J = 8.8 Hz, 2H), 6.72 (s, 1H), 4.57 (t, J = 6.8
Hz, 2H), 3.44 – 3.29 (m, 2H), 2.36 – 2.19 (m, 2H).

13

C NMR (101 MHz, DMSO-d6) δ

145.5, 133.4, 127.4 – 126.9 (m), 124.3, 121.4, 115.9, 115.7, 47.6, 38.8, 28.2. m/z 381.12
M + H (calculated 381.84).
PL421 (7-chloro-N-(3-(4-(4-nitrophenyl)-1H-1,2,3-triazol-1-yl)propyl)quinolin-4amine)
To a stirred solution of PL409 (1 eq, 0.50 g, 1.9 mmol), 1-Ethymyl-4-Nitrobenzene (1 eq,
0.28 g, 1.9 mmol) in tert-butanol (5 ml), CuSO4. 5H2O (0.2 eq, 0.095 g, 0.38 mmol) and
sodium ascorbate (0.4 eq, 0.15 g, 0.76 mmol) in water (5 ml) was added and the mixture
was stirred for 4 hours at 40 oC. After completion, the mixture of solvents was evaporated
and the solid was recrystallized by CHCl3 : MeOH (90:10) to give a pure solid (0.74 g,
95 %). 1H NMR (400 MHz, DMSO-d6) δ 8.85 (s, 1H), 8.36 – 8.25 (m, 3H), 8.12 – 8.04
(m, 2H), 7.82 (s, 1H), 7.43 (dd, J = 9.9, 5.6 Hz, 2H), 6.56 (s, 1H), 4.61 (t, J = 6.9 Hz,
2H), 3.37 (q, J = 6.1 Hz, 2H), 2.37 – 2.12 (m, 2H).

13

C NMR (101 MHz, DMSO-d6) δ

144.4, 125.8, 124.3 (d, J = 11.4 Hz), 123.6, 47.9, 38.8, 28.9, 28.1. m/z 408.11 M + H
(calculated 408.85).
PL422 (N-benzhydrylprop-2-yn-1-amine)
A solution of benzhydramine (1.4 eq, 3 ml, 17 mmol) in anhydrous ether (40ml) was
treated with propargyl bromide in 80% toluene (1 eq, 1.35 ml, 12.2 eq), and catalytic
amount of NaI. The reaction was heated with stirring at 35 oC for 16 hours. After
completion, the reaction mixture was washed with water (2*20ml) and the organic layer
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was dried by anhydrous MgSO4, filtered and concentrated. The crude was purified using
combi-flash chromatography in silica column by eluting in Hexanes:EtOAC (95:5)
mixture to giving a pure yellow solid (1.1 g, 42 %). 1H NMR (400 MHz, Chloroform-d) δ
7.45 – 7.40 (m, 4H), 7.32 – 7.27 (m, 4H), 7.25 – 7.18 (m, 2H), 5.10 (s, 1H), 3.36 (d, J =
2.5 Hz, 2H), 2.25 (t, J = 2.4 Hz, 1H), 1.82 – 1.67 (m, 1H).
PL423 (N-(3-(4-((benzhydrylamino)methyl)-1H-1,2,3-triazol-1-yl)propyl)-7chloroquinolin-4-amine)
To a stirred solution of PL409 (1 eq, 0.55 g, 2.11 mmol), PL422 (1.07 eq, 0.50 g, 2.26
mmol) in tert-butanol (10 ml), a solution of CuSO4. 5.H2O (0.2 eq, 0.10 g, 0.42 mmol)
and sodium ascorbate (0.4 eq, 0.17 g, 0.84 mmol) in water (10ml) was added. The
mixture was stirred for 4 hours at 40 oC. After completion was confirmed by TLC,
chloroform (25 ml) was added and the organic layer was washed by DI-water (3*125 ml),
and then with brine (50 ml). Finally, the organic layer was dried by anhydrous MgSO4 ,
filtered and concentrated. The crude was purified in combi-flash using silica column and
CHCl3 : MeOH (95:5) as eluents obtaining pure solid (0.47 g, 46 %). 1H NMR (400 MHz,
DMSO-d6) δ 8.40 (s, 1H), 8.28 (d, J = 9.1 Hz, 1H), 8.02 (s, 1H), 7.80 (d, 1H), 7.46 (dd, J
= 9.1 Hz, 1H), 7.40 (t, 4H), 7.35 (t, 1H), 7.28 (dt, 4H), 7.18 (t, 2H), 6.45 (d, J = 5.3 Hz,
1H), 5.10 (s, 1H), 4.83 (s, 1H), 4.50 (t, J = 6.9 Hz, 2H), 3.66 (s, 2H), 3.29 (q, J = 6.5 Hz,
2H), 2.23 (p, J = 6.9 Hz, 2H). 13C NMR (101 MHz, DMSO) δ 152.3, 124.6, 124.1, 123.3,
127.9, 128.5, 124.6, 127.4, 128.7, 127.5, 129.4, 128.6, 127.1, 127.6, 99.2, 65.9, 59.7,
47.7, 42.9, 40.0, 28.9. m/z 482.20 M + H (calculated 483.02).
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PL424 (N-(piperidin-4-yl)-5H-cyclopenta[2,1-b:3,4-b']dipyridin-5-imine)
To the protected amine (1 eq, 0.88 g, 2.62 mmol), solid NaOH (10 eq, 1.05 g, 26.2 mmol)
in ethanol (20 eq, 3.1 ml, 52.3 mmol) was added and stirred at room temperature for 2
hours. The solvent was evaporated, and the crude was taken by EtOAC (40 ml) and water
(20 ml). The aqueous layer was extracted with CHCl3 (3 * 20 ml). The two organic layers
were mixed and dried with anhydrous MgSO4, filtered and concentrated to give a
brownish solid (0.37 g, 42 %). 1H NMR (400 MHz, DMSO-d6) δ 8.67 (ddd, J = 8.6, 4.9,
1.5 Hz, 2H), 8.11 (dd, J = 8.0, 1.5 Hz, 1H), 7.95 (dd, J = 7.7, 1.6 Hz, 1H), 7.42 (ddd, J =
20.5, 7.7, 4.9 Hz, 2H), 4.70 (tt, J = 9.1, 4.1 Hz, 1H), 3.97 (ddd, J = 16.4, 7.8, 4.1 Hz, 2H),
3.86 (s, 2H), 2.85 (dq, J = 12.3, 3.7 Hz, 2H), 1.67 (m, 2H).
PL425 (N-(3-(4-((5H-cyclopenta[2,1-b:3,4-b']dipyridin-5-ylidene)amino)piperidin-1yl)propyl)-7-chloroquinolin-4-amine)
PL424 (1.5 eq, 1.1 g, 4.16 mmol) was dissolved in acetonitrile (15 ml), and PL29 (1 eq,
0.87 g, 2.77 mmol) and K2CO3 (2 eq, 0.77 g, 5.44 mmol) were all added. The reaction
mixture was refluxed at 70 oC while stirring for 3 days. After completion, the solvent
was evaporated and the residue was slurred in water (30ml) and vaccum-filtered. The
crude was recrystallized from Toluene:Hexane (50:50) mixture to recover a brownish
solid (0.7 g, 52 %). 1H NMR (400 MHz, DMSO-d6) δ 8.75 (t, J = 5.7 Hz, 4H), 8.38 (dd, J
= 27.1, 6.6 Hz, 4H), 8.27 (d, J = 9.0 Hz, 2H), 8.14 (d, J = 7.5 Hz, 2H), 7.79 (d, J = 2.4
Hz, 2H), 7.56 – 7.40 (m, 10H), 7.30 – 7.08 (m, 8H), 6.52 (d, J = 5.4 Hz, 2H), 4.48 (tt, J =
9.4, 4.7 Hz, 2H), 3.30 (s, 6H), 2.96 (dd, J = 9.7, 5.3 Hz, 3H), 2.49 (s, 1H), 2.29 (d, J = 6.1
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Hz, 9H), 1.97 – 1.78 (m, 11H), 1.30 – 1.21 (m, 1H), 0.84 (dt, J = 10.8, 6.5 Hz, 1H). 13C
NMR (101 MHz, DMSO-d6) δ 160.33 , 158.29 , 155.65 , 152.25 , 151.9, 151.7, 150.1,
149.1, 134.9, 133.3, 132.9, 129.7, 128.9, 128.2, 127.5, 125.3, 124.6, 124.4, 123.9, 117.4,
98.6, 55.9, 51.3, 40.9, 32.9, 25.2, 21.0. m/z 482.20 M + H (calculated 483.02).
PL426 (7-chloro-N-(pyrrolidin-3-yl)quinolin-4-amine)
4,7-dichloroquinoline

(1

eq,

2.5

g,

12.5

mmol)

was

dissolved

in

N,N-

Diisopropylethylamine (50ml). 3-Aminopyrrolidine dihydrochloride (2 eq, 3.98 g, 25
mmol) and CsCO3 (4 eq, 16.45 g, 50 mmol) was added slowly with stirring and the
mixture was refluxed for 4 hours. The solvent was evaporated and the crude was purified
in combi-flash by DCM:MeOH:Et3N (8.9:1:0.1) as mixture of solvents to give orangecolored solid (1.35 g, 44 %). 1H NMR (400 MHz, CDCl3): δ 8.69 (d, J = 4.8, 1H), 8.02
(d, J = 2.0, 1H), 7.90 (d, J = 8.8, 1H), 7.42 (dd, J = 8.8, 2.0, 1H), 6.82 (d, J = 4.8, 1H),
3.83 (m, 1H), 3.68 (m, 1H), 3.42 (m, 1H), 3.14 s, 1H), 2.14 (m, 1H), 1.85 (m, 1H).
PL427 (N-(2-azidoethyl)-7-chloroquinolin-4-amine)
PL30 (1 eq, 6.25 g, 20.8 mmol) was dissolved in dimethylformamide (65ml). Sodium
azide (2 eq, 2.70 g, 41.6 mmol) was added, and the reaction mixture was stirred overnight
at 55 oC. After completion, DI-water (85 ml) was added and the aqueous layer was
extracted with toluene (3 * 250 ml). The organic layer was dried by anhydrous MgSO 4,
filtered and concentrated giving pure solid (5.02 g, 98 %). 1H NMR (400 MHz,
Chloroform-d) δ 8.54 (d, J = 5.4 Hz, 4H), 8.01 (s, 5H), 7.96 (d, J = 2.2 Hz, 4H), 7.83 (d, J
= 9.0 Hz, 4H), 7.34 (dd, J = 9.0, 2.2 Hz, 4H), 7.30 – 7.18 (m, 1H), 7.17 (dt, J = 7.9, 2.2
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Hz, 1H), 6.42 (d, J = 5.3 Hz, 4H), 5.94 (t, J = 5.7 Hz, 4H), 3.66 (dd, J = 6.4, 5.0 Hz, 8H),
3.53 (q, J = 5.6 Hz, 9H), 2.95 (s, 14H), 2.88 (s, 14H), 2.74 (s, 3H), 2.35 (s, 1H).
General procedure for the synthesis of terminal alkynes:
The 10 terminal alkynes PL428, PL429, PL430, PL431, PL432, PL433, PL434, PL435,
PL436 and PL437 were prepared according to the following procedure:
To a mixture of N-substituted piperazine (1 eq, 3.2 mmol) and anhydrous K2CO3 (1 eq,
0.44 g, 3.2 mmol) in anhydrous acetonitrile (5 mL), propargyl bromide (80% W/V
solution in toluene, 1 eq , 0.36 ml, 3.2 mmol) was added. The mixture was stirred
overnight under reflux, and then filtered and evaporated. The residue was purified by
combiflash chromatography using silica column eluting by Hexanes:EtOAc mixture.
PL428 (2-(4-(prop-2-yn-1-yl)piperazin-1-yl)pyrimidine)
0.21 g, 32 %. 1H NMR (400 MHz, DMSO-d6) δ 8.47 (dd, J = 11.1, 2 Hz, 11H), 6.79 (dt,
J = 14.5, 4.9 Hz, 1H), 4.68 (s, 2H), 4.17 (s, 1H), 4.14 (dd, J = 13.0, 8.0 Hz, 4H), 3.67 (t, J
= 5.1 Hz, 4H).
PL429 (1-(prop-2-yn-1-yl)-4-(4-(trifluoromethyl)benzyl)piperazine)
0.78 g, 87 %. 1H NMR (400 MHz, Chloroform-d) δ 7.56 (dd, 2H), 7.47 (dd, J = 11.2, 8.0
Hz, 2H), 3.96 (t, J = 5.1 Hz, 2H), 3.56 (d, J = 18.7 Hz, 2H), 3.30 (d, J = 2.5 Hz, 2H), 3.09
– 2.93 (m, 2H), 2.68 – 2.58 (m, 4H), 2.26 (t, J = 2.4 Hz, 1H).
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PL430 (1-(prop-2-yn-1-yl)-4-(p-tolyl)piperazine)
0.68 g, 99 %. 1H NMR (400 MHz, Chloroform-d) δ 7.14 – 7.02 (m, 2H), 6.93 – 6.74 (m,
2H), 3.45 – 3.23 (m, 2H), 3.22 – 3.10 (m, 4H), 2.78 – 2.70 (m, 4H), 2.27 (d, J = 6.0 Hz,
3H).
PL431 (1-(prop-2-yn-1-yl)-4-(pyridin-2-yl)piperazine)
0.45 g, 70 %. 1H NMR (400 MHz, Chloroform-d) δ 8.19 (tt, J = 4.9, 2.1 Hz, 1H), 7.63 –
7.43 (m, 1H), 6.86 – 6.59 (m, 2H), 4.12 – 3.95 (m, 2H), 3.90 (t, J = 5.2 Hz, 2H), 3.71 –
3.44 (m, 2H), 3.36 (d, J = 2.5 Hz, 2H), 2.73 – 2.65 (m, 2H), 2.28 (t, J = 2.5 Hz, 1H).
PL432 (1-(4-(oxo-λ6-methyl)phenyl)-4-(prop-2-yn-1-yl)piperazine)
1-(4-methoxyphenyl)-piperazine dihydrochloride (1 eq, 2 g, 7.5 mmol) was dissolved in
water (20ml), and solid NaHCO3 (2.3 eq, 1.4 g, 17.1 mmol) was added with stirring.
After addition of dichloromethane (25 ml), the aqueous phase was extracted with DCM
(3 * 25ml) and the organic phase was dried by anhydrous MgSO4, filtered and
concentrated by rotovap to give the free base starting material.
0.7 g, 95 %. 1H NMR (400 MHz, Chloroform-d) δ 7.02 – 6.78 (m, 4H), 3.76 (d, J = 2.5
Hz, 3H), 3.36 (d, J = 2.5 Hz, 2H), 3.17 – 2.98 (m, 4H), 2.78 – 2.55 (m, 4H), 2.28 (t, J =
2.4 Hz, 1H).

95

PL433 (1-phenyl-4-(prop-2-yn-1-yl)piperazine)
0.56 g, 88 %. 1H NMR (400 MHz, Chloroform-d) δ 7.33 – 7.20 (m, 2H), 6.98 – 6.80 (m,
3H), 3.36 (d, J = 2.5 Hz, 2H), 3.27 – 3.20 (m, 4H), 2.77 – 2.70 (m, 4H), 2.28 (t, J = 2.4
Hz, 1H).
PL434 (4-(4-(prop-2-yn-1-yl)piperazin-1-yl)phenol)
0.39 g, 57 %. 1H NMR (400 MHz, DMSO-d6) δ 6.91 – 6.59 (m, 4H), 4.62 (d, J = 2.6 Hz,
2H), 4.15 (t, 1H), 3.68 (t, J = 5.0 Hz, 2H), 3.39 (t, J = 4.8 Hz, 2H), 3.17 (s, 1H), 3.13 –
3.01 (m, 4H).
PL435 (1-(4-chlorophenyl)-4-(prop-2-yn-1-yl)piperazine)
0.5 g, 67 %. 1H NMR (400 MHz, Chloroform-d) δ 7.27 – 7.15 (m, 2H), 6.91 – 6.78 (m,
2H), 3.37 (d, J = 2.4 Hz, 2H), 3.26 – 3.16 (m, 4H), 2.78 – 2.69 (m, 4H), 2.28 (t, J = 2.5
Hz, 1H).
PL436 (1-cyclohexyl-4-(prop-2-yn-1-yl)piperazine)
0.57 g, 86 %. 1H NMR (400 MHz, Chloroform-d) δ 3.34 (d, J = 2.5 Hz, 2H), 3.10 (dtd,
4H), 2.42 – 2.26 (m, 3H), 1.95 (m, 2H), 1.53 (qd, J = 12.1, 3.4 Hz, 4H), 1.27 (m, 6H).
PL437 (1-(3,4-dichlorophenyl)-4-(prop-2-yn-1-yl)piperazine)
0.81 g, 94 %. 1H NMR (400 MHz, Chloroform-d) δ 7.39 – 7.22 (m, 1H), 7.01 – 6.84 (m,
1H), 6.74 (ddd, J = 8.9, 4.9, 2.9 Hz, 1H), 3.41 – 3.29 (m, 2H), 3.25 – 3.10 (m, 4H), 2.80 –
2.68 (m, 4H), 2.29 (t, J = 2.4 Hz, 1H).
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PL439 (N1,N3-bis(7-chloroquinolin-4-yl)propane-1,3-diamine)
To PL426 (1.5 eq, 0.88 g, 3.57 mmol) dissolved in acetonitrile (30ml), PL29 (1 eq, 0.75
g, 2.38 mmol) and cesium carbonate (2 eq, 1.55 g, 4.76 mmol) was added. The reaction
mixture was refluxed for 3 days. The solvent was evaporated and the crude was slurred in
water (80 ml) in a sonicator for 30 minutes. The solid was filtered by vaccum-filtration
and purified on silica column using combi-flash chromatography eluting by
EtOAC:MeOH. One of the peaks (collection 3) was collected and concentrated to give a
yellow solid (0.1 g, 67 %). 1H NMR (400 MHz, Chloroform-d) δ 8.74 (d, J = 5.2 Hz,
1H), 8.58 – 8.43 (m, 1H), 8.12 (d, J = 8.9 Hz, 1H), 8.05 (d, J = 2.0 Hz, 1H), 8.01 – 7.91
(m, 1H), 7.66 (d, J = 9.0 Hz, 1H), 7.45 (dd, J = 8.9, 2.1 Hz, 1H), 7.40 – 7.26 (m, 1H),
6.73 (d, J = 5.3 Hz, 1H), 6.49 (d, J = 5.4 Hz, 1H), 5.43 (s, 1H), 4.38 (t, J = 5.6 Hz, 2H),
3.69 (q, J = 6.3 Hz, 2H), 2.43 (p, J = 6.3 Hz, 2H). m/z 397.08 M + H (calculated 397.30).
General procedure for the synthesis of piperazine-linked triazoles:
The 9 compounds PL440, PL441, PL442, PL443, PL444, PL445, PL446, PL447 and
PL448 were prepared according to the following procedure:
To a stirred solution of PL409 (1 eq, 0.25 g, 0.95 mmol) and synthesized N-piperazinylsubstituted terminal alkynes (1.05 eq, 1.0 mmol) in tert-butanol (6.8 ml), CuSO4. 5H2O
(0.1 eq, 0.024 g, 0.095 mmol) and sodium ascorbate (0.2 eq, 0.038 g, 0.19 mmol) in
water (2.3 ml) was added. The mixture was stirred for 48 hours at 50 oC. After
completion, the mixture of solvents was evaporated and the solid was purified using
combi-flash chromatography in silica column by eluting using CHCl3:MeOH (90:10).
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PL440 (7-chloro-N-(3-(4-((4-(pyrimidin-2-yl)piperazin-1-yl)methyl)-1H-1,2,3triazol-1-yl)propyl)quinolin-4-amine)
0.32 g, 70 %. 1H NMR (400 MHz, DMSO-d6) δ 8.39 (d, J = 5.4 Hz, 1H), 8.34 (d, J = 4.8
Hz, 2H), 8.26 (d, J = 9.0 Hz, 1H), 8.07 (s, 1H), 7.79 (d, J = 2.3 Hz, 1H), 7.47 (dd, J = 9.0,
2.0 Hz, 1H), 7.35 (t, J = 5.4 Hz, 1H), 6.61 (t, J = 4.8 Hz, 1H), 6.42 (d, J = 5.4 Hz, 1H),
4.49 (t, J = 6.9 Hz, 2H), 3.69 (t, J = 5.0 Hz, 4H), 3.60 (s, 2H), 3.28 (q, J = 6.5 Hz, 2H),
2.44 (t, J = 5.0 Hz, 4H), 2.24 (h, J = 7.4, 7.0 Hz, 2H). 13C NMR (101 MHz, DMSO-d6) δ
157.1, 141.3, 136.2, 129.7, 123.9, 110.1, 52.0, 47.2, 43.4, 38.9, 28.2 (d, J = 20.9 Hz). m/z
463.20 M + H (calculated 463.97).
PL441 (7-chloro-N-(3-(4-((4-(4-(trifluoromethyl)benzyl)piperazin-1-yl)methyl)-1H1,2,3-triazol-1-yl)propyl)quinolin-4-amine)
0.16 g, 52 %. 1H NMR (400 MHz, DMSO-d6) δ 8.39 (d, J = 5.4 Hz, 1H), 8.26 (d, J = 9.0
Hz, 1H), 8.01 (s, 1H), 7.79 (d, J = 2.3 Hz, 1H), 7.66 (d, J = 8.0 Hz, 2H), 7.50 (d, J = 8.0
Hz, 2H), 7.47 (dd, J = 9.0, 2.0 Hz, 1H), 7.36 (t, J = 5.3 Hz, 1H), 6.41 (d, J = 5.5 Hz, 1H),
4.49 (t, J = 6.9 Hz, 2H), 3.54 (d, J = 5.2 Hz, 4H), 3.27 (q, J = 6.5 Hz, 2H), 2.36 (s, 8H),
2.22 (p, J = 6.9 Hz, 2H). 13C NMR (101 MHz, DMSO-d6) δ 151.7, 150.0, 148.8, 143.2,
133.5, 129.3, 127.3, 125.0, 124.2, 124.0, 123.9, 120.9, 117.4, 98.7, 61.2, 52.4, 52.1, 47.2,
28.4. m/z 543.22 M + H (calculated 544.02).
PL442 (7-chloro-N-(3-(4-((4-(p-tolyl)piperazin-1-yl)methyl)-1H-1,2,3-triazol-1yl)propyl)quinolin-4-amine)
0.17 g, 35 %. 1H NMR (400 MHz, DMSO-d6) δ 8.40 (d, J = 5.4 Hz, 1H), 8.26 (d, J = 9.0
Hz, 1H), 8.06 (s, 1H), 7.80 (s, J = 2.3 Hz, 1H), 7.47 (dd, J = 9.0, 2.0 Hz, 1H), 7.37 (t, J =
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5.2 Hz, 1H), 7.00 (d, J = 8.3 Hz, 2H), 6.84 – 6.76 (m, 2H), 6.42 (t, J = 6.4 Hz, 1H), 4.49
(q, J = 6.8 Hz, 2H), 3.60 (s, 2H), 3.27 (s, 2H), 3.06 – 2.99 (m, 4H), 2.50 (d, J = 1.8 Hz,
4H), 2.38 (d, J = 13.8 Hz, 2H), 2.32 – 2.16 (m, 3H). 13C NMR (101 MHz, DMSO-d6) δ
151.0, 150.0, 133.5, 128.9, 124.2, 118.8, 115.3, 52.2, 48.1, 47.3, 28.4. m/z 475.23 M + H
(calculated 476.03).
PL443 (7-chloro-N-(3-(4-((4-(pyridin-2-yl)piperazin-1-yl)methyl)-1H-1,2,3-triazol-1yl)propyl)quinolin-4-amine)
0.28 g, 61 %. 1H NMR (400 MHz, DMSO-d6) δ 8.43 – 8.37 (m, 1H), 8.27 (d, J = 9.0 Hz,
1H), 8.17 – 8.05 (m, 2H), 7.80 (d, J = 2.3 Hz, 1H), 7.56 – 7.39 (m, 3H), 6.79 (d, J = 8.6
Hz, 1H), 6.62 (dd, J = 7.0, 4.9 Hz, 1H), 6.44 (d, J = 5.5 Hz, 1H), 4.50 (t, J = 6.9 Hz, 2H),
3.60 (s, 2H), 3.44 (t, J = 4.9 Hz, 4H), 3.29 (s, 2H), 2.47 (d, J = 5.0 Hz, 4H), 2.23 (p, J =
6.9 Hz, 2H). 13C NMR (101 MHz, DMSO-d6) δ 147.5, 137.5, 124.3, 113.0, 107.1, 47.3,
40.1, 38.8, 28.3. m/z 462.21 M + H (calculated 462.99).
PL444 (7-chloro-N-(3-(4-((4-(4-methoxyphenyl)piperazin-1-yl)methyl)-1H-1,2,3triazol-1-yl)propyl)quinolin-4-amine)
0.37 g, 76 %. 1H NMR (400 MHz, DMSO-d6) δ 8.41 (s, 1H), 8.29 (d, J = 9.1 Hz, 1H),
8.06 (s, 1H), 7.80 (d, J = 2.3 Hz, 1H), 7.55 – 7.46 (m, 2H), 6.90 – 6.75 (m, 4H), 6.46 (d, J
= 5.4 Hz, 1H), 4.50 (t, J = 6.8 Hz, 2H), 3.68 (d, J = 9.3 Hz, 3H), 3.60 (s, 2H), 3.24 – 3.15
(m, 2H), 2.97 (t, J = 4.9 Hz, 4H), 2.53 (d, J = 4.9 Hz, 4H), 2.24 (p, J = 6.9 Hz, 2H). 13C
NMR (101 MHz, DMSO-d6) δ 124.3, 117.3, 114.2, 55.1, 38.8. m/z 491.22 M + H
(calculated 492.02).

99

PL445 (7-chloro-N-(3-(4-((4-phenylpiperazin-1-yl)methyl)-1H-1,2,3-triazol-1yl)propyl)quinolin-4-amine)
0.32 g, 70 %. 1H NMR (400 MHz, DMSO-d6) δ 8.40 (d, J = 5.4 Hz, 1H), 8.34 – 8.23 (m,
1H), 8.07 (s, 1H), 7.80 (d, J = 2.3 Hz, 1H), 7.47 (dd, J = 9.0, 2.2 Hz, 1H), 7.37 (t, J = 5.3
Hz, 1H), 7.27 – 7.14 (m, 2H), 6.90 (d, J = 8.2 Hz, 2H), 6.76 (t, J = 7.2 Hz, 1H), 6.43 (d, J
= 5.4 Hz, 1H), 4.51 (t, J = 6.9 Hz, 2H), 3.60 (s, 2H), 3.27 (d, J = 6.5 Hz, 2H), 3.08 (t, J =
4.9 Hz, 4H), 2.52 (t, J = 4.9 Hz, 4H), 2.24 (p, J = 6.9 Hz, 2H).

13

C NMR (101 MHz,

DMSO-d6) δ 151.0, 150.0, 133.5, 128.9, 124.2, 118.8, 115.3, 52.2, 48.1, 47.3, 28.4. m/z
461.21 M + H (calculated 462.00).
PL446 (4-(4-((1-(3-((7-chloroquinolin-4-yl)amino)propyl)-1H-1,2,3-triazol-4yl)methyl)piperazin-1-yl)phenol)
0.33 g, 68 %. 1H NMR (400 MHz, DMSO-d6) δ 8.79 (s, 1H), 8.42 – 8.23 (m, 3H), 8.06
(d, J = 5.2 Hz, 1H), 7.79 (d, J = 2.3 Hz, 1H), 7.47 (dd, J = 9.0, 2.2 Hz, 1H), 7.36 (t, J =
5.5 Hz, 1H), 6.84 – 6.70 (m, 1H), 6.67 – 6.57 (m, 1H), 6.42 (d, J = 5.4 Hz, 1H), 4.50 (td,
J = 6.9, 2.1 Hz, 2H), 3.69 (t, J = 5.0 Hz, 2H), 3.59 (d, J = 3.8 Hz, 2H), 2.91 (t, J = 4.9 Hz,
4H), 2.44 (t, J = 5.1 Hz, 2H), 2.23 (p, J = 6.9 Hz, 2H). 13C NMR (101 MHz, DMSO-d6) δ
157.8, 149.8, 133.5, 124.12 (d, J = 11.1 Hz), 117.7, 115.4, 56.6, 52.4, 49.8, 47.3, 38.7,
28.4. m/z 477.21 M + H (calculated 478.00).
PL447 (7-chloro-N-(3-(4-((4-(4-chlorophenyl)piperazin-1-yl)methyl)-1H-1,2,3triazol-1-yl)propyl)quinolin-4-amine)
0.40 g, 80 %. 1H NMR (400 MHz, DMSO-d6) δ 8.80 (s, 1H), 8.42 – 8.36 (m, 3H), 8.27
(d, J = 9.1 Hz, 3H), 8.06 (d, J = 2.2 Hz, 3H), 7.79 (d, J = 2.3 Hz, 3H), 7.47 (dd, J = 9.0,
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2.2 Hz, 4H), 7.36 (t, J = 5.1 Hz, 4H), 7.28 – 7.17 (m, 4H), 7.00 – 6.87 (m, 4H), 6.79 –
6.70 (m, 2H), 6.67 – 6.58 (m, 2H), 6.42 (d, J = 5.4 Hz, 3H), 5.78 – 5.73 (m, 1H), 4.50 (t,
J = 6.9 Hz, 2H), 3.59 (d, J = 3.7 Hz, 2H), 3.26 (s, 2H), 3.08 (t, J = 5.0 Hz, 4H), 2.91 (dd, J
= 9.5, 4.5 Hz, 2H), 2.52 (s, 2H), 2.24 (h, J = 6.7 Hz, 2H). 13C NMR (101 MHz, DMSOd6) δ 150.2, 149.7, 133.7, 128.5, 127.5, 127.1, 124.2 (d, J = 8.4 Hz), 123.9, 122.3, 116.8,
52.4, 52.0, 47.9, 47.3, 38.8, 28.4. m/z 495.17 M + H (calculated 496.44).
PL448 (7-chloro-N-(3-(4-((4-(3,4-dichlorophenyl)piperazin-1-yl)methyl)-1H-1,2,3triazol-1-yl)propyl)quinolin-4-amine)
0.41 g, 77 %. 1H NMR (400 MHz, DMSO-d6) δ 8.40 (s, 1H), 8.27 (d, J = 9.0 Hz, 1H),
8.06 (s, 1H), 7.79 (d, J = 2.3 Hz, 1H), 7.51 – 7.34 (m, 3H), 7.10 (d, J = 2.9 Hz, 1H), 7.00
– 6.87 (m, 1H), 6.43 (d, J = 5.4 Hz, 1H), 4.50 (t, J = 6.9 Hz, 2H), 3.56 (d, J = 26.0 Hz,
2H), 3.32 – 3.24 (m, 2H), 3.13 (t, J = 5.0 Hz, 4H), 2.56 (s, 4H), 2.24 (h, J = 6.6 Hz, 2H).
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C NMR (101 MHz, DMSO-d6) δ 156.2, 152.2, 150.3, 133.5, 128.0, 127.2, 126.1,

125.7, 124.1, 123.9, 109.4, 52.0, 51.7, 47.3, 38.9, 28.3. m/z 530.14 M + H (calculated
530.88).
PL456 (7-chloro-N-(3-(4-((4-(7-chloroquinolin-4-yl)piperazin-1-yl)methyl)-1H-1,2,3triazol-1-yl)propyl)quinolin-4-amine)
The purified PL467 (1.07 eq, 1.15 g, 4.02 mmol) and PL409 (1 eq, 0.99 g, 3.76 mmol)
dissolved in tert-butanol (15 ml) were mixed with CuSO4. 5H2O (0.15 eq, 0.14 g, 0.56
mmol) and sodium ascorbate (0.3 eq, 0.22 g, 1.13 mmol) in water (5 ml) for 24 hours at
50

o

C. After evaporating the solvent, the crude was purified using combi-flash

chromatography on silica by eluting in CHCl3:MeOH (90:10) to give the target
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compound (1.2 g, 57 %). 1H NMR (400 MHz, CDCl3) δ 8.70 (d, J = 5.0 Hz, 1H), 8.47 (d,
J = 5.3 Hz, 1H), 8.03 (d, J = 2.1 Hz, 1H), 7.94 (d, J = 2.2 Hz, 1H), 7.91 (d, J = 8.9 Hz
1H), 7.75 (d, J = 9.0 Hz, 1H), 7.57 (s, 1H), 7.41 (dd, J = 9.0, 2.1 Hz, 1H), 7.40 (dd, J =
9.0, 2.3 Hz, 1H), 6.80 (d, J = 5.0 Hz, 1H), 6.36 (d, J = 5.4 Hz, 1H), 5.87 (t, J = 5.5 Hz,
1H), 4.57 (t, J = 6.2 Hz, 2H), 3.78 (s, 2H), 3.47 (d, 2H), 3.20 (t, 4H), 2.77 (t, 4H), 2.39 (p,
J = 6.5 Hz, 2H). 13C NMR (101 MHz, DMSO-d6) δ 156.8, 151.8, 150.9, 150.1, 149.8,
144.8, 135.5, 134.9, 128.8, 126.2, 125.8, 125.1, 123.6, 123.2, 121.9, 121.5, 108.9, 98.6,
53.2, 52.8, 51.9, 48.1, 40.3, 28.3. m/z 547.19 M + H (calculated 547.49).
PL457 (7-chloro-4-isothiocyanatoquinoline)
A mixture of 4,7-dichloroquinoline (1 eq, 1.8 g, 9.09 mmol) and silverthiocyanate (2 eq,
3.02 g, 18.18 mmol) was stirred in anhydrous toluene (15 ml) for 12 hours. The reaction
was carried in disposable screw cap culture tube (100 ml) using fishr PTFE disposable
bar stirrer. The hot mixture was filtered and the filtrate was washed with chloroform (3 *
37.5 ml) and concentrated by rotovap to give a yellow solid (1.88 g , 94 %). 1H NMR
(400 MHz, Chloroform-d) δ 8.86 (d, J = 4.7 Hz, 1H), 8.12 (d, J = 2.0 Hz, 1H), 8.03 (d, J
= 8.9 Hz, 1H), 7.58 (dd, J = 8.9, 2.1 Hz, 1H), 7.26 (d, J = 4.7 Hz, 1H).
PL459 (Methyl (3-((7-chloroquinolin-4-yl)amino)propyl)carbamodithioate)
The intermediate product was synthesized in one-pot reaction by dissolving PL107 (1 eq,
2.0 , 8.49 mmol) in dimethylsulfoxide (4 ml) and stirring at room temperature. Carbon
disulfide (1.25 eq, 0.64 ml, 10.61 mmol) and 10 % NaOH (1.25 eq, 3.78 ml, 10.61 mmol)
were added dropwise over 30 minutes. Then the mixture was stirred for another 30
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minutes. After 1 hour, dimethylsulfate (1 eq, 0.81 ml, 8.49 mmol) was added at 5-10 oC,
and the stirring continued for 3 hours. The sticky-brownish suspension formed was added
to ice-water (50 ml) and transferred to sep-funnel. The aqueous layer was extracted by
chloroform (3 * 20 ml). The organic layer was washed by saturated NaHCO3 (25 ml) and
then salted out by brine (20 ml). Finally the organic layer was dried by anhydrous
MgSO4, filtered and concentrated to give brownish solid (0.8 g, 30 %). 1H NMR (400
MHz, DMSO-d6) δ 9.99 (t, J = 5.2 Hz, 1H), 8.40 (d, J = 5.4 Hz, 1H), 8.25 (d, J = 9.0 Hz,
1H), 7.80 (d, J = 2.3 Hz, 1H), 7.52 – 7.27 (m, 2H), 6.49 (t, J = 6.0 Hz, 1H), 3.66 (dtd, J =
43.9, 6.9, 4.3 Hz, 2H), 3.32 (q, J = 6.6 Hz, 2H), 2.52 (d, J = 2.4 Hz, 3H), 1.99 (m, 2H).
PL460 (Ethyl 4-((5H-cyclopenta[2,1-b:3,4-b']dipyridin-5-ylidene)amino)piperidine1-carboxylate)
1,8-Diazafluoren-9-one (1 eq, 0.5 g, 2.74 mmol) and Ethyl-4-amino-1-piperidine
carboxylate (1.15 eq, 0.54 ml, 3.15 mmol) was dissolved in anhydrous toluene (15 ml).
Catalytic amount of p-toluene-sulfonic acid was added and the reaction was performed
using dean-stark apparatus to remove the water continuously forming as a by-product.
The reaction was refluxed stirring for 3 days. After the mixture was cooled to RT, the
solvent was evaporated, and the crude was used in the next reaction prior to purification
(0.88 g, 96 %). 1H NMR (400 MHz, DMSO-d6) δ 8.75 (ddd, J = 8.6, 4.9, 1.5 Hz, 2H),
8.42 (dd, J = 8.0, 1.5 Hz, 1H), 8.12 (dd, J = 7.7, 1.6 Hz, 1H), 7.49 (ddd, J = 20.5, 7.7, 4.9
Hz, 2H), 4.70 (tt, J = 9.1, 4.1 Hz, 1H), 4.09 (q, J = 7.1 Hz, 2H), 3.99 (ddd, J = 16.4, 7.8,
4.1 Hz, 2H), 3.27 (s, 2H), 1.91 (dq, J = 12.3, 3.7 Hz, 2H), 1.80 – 1.62 (m, 2H), 1.20 (dt, J
= 16.9, 7.1 Hz, 3H).
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PL467 (7-chloro-4-(4-(prop-2-yn-1-yl)piperazin-1-yl)quinoline)
PL49 (1 eq, 2.5 g, 10.1 mmol), propargyl bromide in 80 % W/V toluene (1 eq, 0.96 ml,
10.1 mmol) and K2CO3 (1 eq, 1.4 g, 10.1 mmol) in acetonitrile (15 ml) were refluxed for
48 hours. After the completion of the reaction was confirmed by TCL on alumina plate
using EtOAC:MeOH (90:10) as eluents, the solvent was evaporated by rotovap. The
crude was taken up by dichloromethane (40 ml) and washed by saturated NaHCO3 (3 *
20 ml). All the aqueous phase were mixed and and extracted by DCM (30 ml). The two
organic phases were mixed and dried by anhydrous MgSO4, filtered and concentrated.
The crude was purified using combi-flash chromatography on silica using
Hexanes:EtOAC as eluents give brownish solid (2.41 g, 83 %). 1H NMR (400 MHz,
CDCl3) δ 8.71 (d, J = 5.0 Hz, 1H), 8.03 (d, J = 2.1 Hz, 1H), 7.94 (d, J = 8.9 Hz, 1H), 7.41
(dd, J = 9.0, 2.1 Hz, 1H), 6.83 (d, J = 5.0 Hz, 1H), 3.44 (d, 2H), 3.27 (t, 4H), 2.86 (t, 4H),
2.35 (t, 1H).
7.3. In Vitro Drug Susceptibility Assays
Both CQS (D6) and CQR (Dd2 and 7G8) P. falciparum maintained continuously in
culture were used. Asynchronous cultures were diluted with uninfected RBCs and
complete medium (RPMI-1640 with 0.5% Albumax II) to achieve 0.2% parasitemia and
2% hematocrit. In 96-well microplates, CQ (positive control) or click compounds diluted
in complete medium from 10 mM stock in DMSO were added to the cell mixture to yield
triplicate wells with drug concentrations ranging from 0 to 10-4 M in a final well volume
of 100 μL. After 72 h of incubation under standard culture conditions, plates were
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harvested and read by the SYBR Green I fluorescence-based method using a 96-well
fluorescence plate reader (Gemini-EM, Molecular Devices), with excitation and emission
wavelengths at 497 and 520 nm, respectively. The fluorescence readings were plotted
against log[drug], and the IC50 values were obtained from curve fitting performed by
nonlinear regression using either Prism (GraphPad) or Excel (Microsoft) software. The
values obtained for each cell line are normalized to CQ values of 5.9 nM for D6, 54 nM
for Dd2, and 57 nM for 7G8. Errors were estimated to be ± 30%. This was determined by
looking at the variability in IC50 values of 4 compounds, each with 3 or 4 sets of results
per IC50 determination, and by taking into account the estimated uncertainties resulting
from the weighing of the compounds.
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APPENDICES
Appendix A: List of Intermediate Compounds Synthesized
PL No.
PL16

Structure

PL No.
PL28

PL29

PL30

PL49

PL107

PL190

PL46

PL294

PL323

PL326

PL334

PL409

PL422

Structure
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PL424

PL426

PL427

PL428

PL429

PL430

PL431

PL432

PL433

PL434

PL435

PL436

PL437

PL457
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PL458

PL459

PL460

PL467
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Appendix B: List of Target Compounds Synthesized

PL
No.

Click Compound

IC50
(D6,
Dd2,
7G8)

HBD/
HBA

NRot

CLogP

Mol.Wt

CQ

5.9
54
57

1/3

8

4.75

305.85

369

>250
>250
>250

1/5

8

5.63

450.59

370

>250
>250
>250

1/4

8

6.37

436.60

403

10.4
12.8
14.5

1/6

8

6.28

447.85

404

25
81.6
48

2/6

8

4.84

469.97

405

98.6
210
192

1/6

7

4.61

393.88

121

406

52.4
120
122

1/6

7

5.17

393.88

407

81.0
109
129

1/5

6

5.37

381.84

408

22.7
39.1
95.7

1/5

6

5.44

399.83

410

9.6
<2.5
<2.5

1/4

12

8.97

528.02

411

76.8
87.5
151

1/5

6

5.19

363.85

412

423
696
592

1/6

6

4.07

364.84
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413

40.5
61.4
60

1/5

6

5.69

377.88

414

9.6
77.7
85.8

1/5

7

4.93

377.88

415

76.8
345
238

2/6

6

4.05

378.86

416

423
30.7
49.6

1/5

6

6.09

442.75

417

40.5
109
140

1/6

8

5.17

393.88

418

18.8
42.7
36.6

1/5

6

5.94

398.29
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419

11
31.6
18.7

1/5

7

6.13

431.85

420

39.6
85.2
80.3

1/5

6

5.37

381.84

421

18.8
50.5
44.5

1/8

7

5.01

408.85

423

80.3
160
189

2/6

10

4.96

483.02

425

20.5
32.5
86

1/6

6

4.08

483.02

439

2.5
4
2.5

2/4

6

6.87

397.30
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440

67
>250
>250

1/9

8

3.11

463.97

441

10
40
16

1/7

10

6.00

544.02

442

12
37
18

1/7

8

5.33

476.03

443

41
>250
>250

1/8

8

3.88

462.99

444

33
68
65

1/8

10

4.85

492.02

445

17
67
74

1/7

8

4.83

462.00
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446

155
94.4
>250

2/8

8

4.16

478.00

447

8.8
26.5
19

1/7

8

5.71

496.44

448

6.8
15.2
11

1/7

8

6.36

530.88

456

0.5
10
11

1/8

8

6.04

547.49
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Appendix C: Selected Spectral and Chromatography Data
1

H-Proton spectroscopy, COSY, HSQC, HMBC, NOESY,

13

C-Spectroscopy, mass

spectroscopy and combiflash chromatography data of selected compounds:

PL403

PL410

PL448

PL456
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Figure 1.1. 1H-proton spectrum of PL403
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Figure 1.2. COSY spectrum of PL403

129

Figure 1.3. HSQC spectrum of PL403

130

Figure 1.4. HMBC spectrum of PL403

131

Figure 1.5. NOESY spectrum of PL403

132

Figure 1.6. 13C-spectrum of PL403

133

Figure 1.7. Mass spectrum of PL403
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Figure 2.1. 1H-proton spectrum of PL410

135

Figure 2.2. COSY spectrum of PL410

136

Figure 2.3. HSQC spectrum of PL410
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Figure 2.4. HMBC spectrum of PL410

138

Figure 2.5. NOESY spectrum of PL410

139

Figure 2.6. 13C-spectrum of PL410

140

Figure 2.7. Mass spectrum of PL410
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Figure 2.8. Combiflash chomatography of PL410

142

Figure 3.1. 1H-proton spectrum of PL448

143

Figure 3.2. COSY spectrum of PL448

144

Figure 3.3. HSQC spectrum of PL448

145

Figure 3.4. HMBC spectrum of PL448

146

Figure 3.5. NOESY spectrum of PL448

147

Figure 3.6. 13C-Specrum of PL448

148

Figure 3.7. Mass spectrum of PL448
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Figure 3.8. Combiflash chromatography of PL448
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Figure 4.1. 1H-proton spectrum of PL456
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Figure 4.2. COSY spectrum of PL456
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Figure 4.3. HSQC spectrum of PL456
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Figure 4.4. HMBC spectrum of PL456
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Figure 4.5. NOESY spectrum of PL456

155

Figure 4.6. 13C-Spectrum of PL456

156

Figure 4.7. Mass spectrum of PL456

157

Figure 4.8. Combiflash Chromatography of PL456

158

